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ABSTRACT 
Background: Cannabis and its main psychoactive ingredient delta-9-
tetrahydrocannibidiol (THC), can induce transient psychotic symptoms in healthy 
individuals and exacerbate them in those with established psychosis. However, 
not everyone experiences these effects, suggesting that certain individuals are 
particularly susceptible. The neural basis of this sensitivity to the 
psychotomimetic effects of THC is unclear.  
Methods: We investigated whether individuals who are sensitive to the 
psychotomimetic effects of THC (TP) under experimental conditions would show 
differential hippocampal activation compared to those who are not (NP). We 
studied 36 healthy males under identical conditions under the influence of 
placebo or THC (10 mg) given orally, on two separate occasions, in a pseudo-
randomised, double-blind, repeated measures, within-subject, cross-over design, 
using psychopathological assessments and functional MRI while they performed 
a verbal learning task. They were classified into those who experienced transient 
psychotic symptoms (TP; n=14) following THC administration and those who did 
not (NP; n=22). Results: Under placebo conditions, there was significantly 
greater engagement of the left hippocampus (p<0.001) in the TP group compared 
to the NP group during verbal encoding, which survived leave-one-out analysis. 
The level of hippocampal activation was directly correlated (spearman’s rho= 
0.44, p=0.008) with the severity of transient psychotic symptoms induced by 
THC. This difference was not present when we compared two subgroups from the 
same sample that were defined by sensitivity to anxiogenic effects of THC.  
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Conclusions: These results suggest that altered hippocampal activation during 
verbal encoding may serve as a marker of sensitivity to the acute 
psychotomimetic effects of THC.  
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Introduction 
Regular cannabis use is associated with a dose-dependent increase in the risk of onset 
(Moore et al., 2007, Zammit et al., 2002) and exacerbation (Patel et al., 2016, 
Schoeler et al., 2016b, Schoeler et al., 2016c, Schoeler et al., 2016d) of psychotic 
disorders such as schizophrenia. Consistent with this, delta-9-tetrahydrocannabinol 
(THC), the main psychoactive ingredient in cannabis has been shown in experimental 
studies to induce transient psychotic symptoms in healthy subjects (Bhattacharyya et 
al., 2015a, Bhattacharyya et al., 2009, D'Souza et al., 2004, Morrison et al., 2011) 
and exacerbate them in schizophrenia patients (D'Souza et al., 2005, Henquet et al., 
2006).  
 
However, there is marked variation in the psychotomimetic and cognitive effects of 
cannabis based on genetic (Bhattacharyya et al., 2012a, Bhattacharyya et al., 2014) 
and personality and familial factors (Di Forti et al., 2012, Henquet et al., 2005, 
McGuire et al., 1995, Stirling et al., 2008, van Winkel et al., 2011) as well as the 
composition of cannabis (Bhattacharyya et al., 2010). Experimental studies in healthy 
individuals suggest that even when given substantial doses of pure THC, not all will 
experience a state of transient psychosis (Atakan et al., 2013, Bhattacharyya et al., 
2010). While this may point towards fundamental neurobiological differences 
between those who are susceptible to the psychotomimetic effects of THC and those 
who are not, it is unclear if this is the case.   
 
Evidence from animal models has led to the hypothesis that the development of 
psychosis may be associated with increased hippocampal activity (Lodge and Grace, 
2007), in turn driving striatal dopaminergic overactivity (Lodge and Grace, 2011). 
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This is consistent with evidence of increased resting hippocampal regional cerebral 
blood flow (Allen et al., 2015) and increased hippocampal activation during memory 
tasks (Valli et al., 2011) in individuals at high risk of developing psychosis (Allen et 
al., 2015). The hippocampus has a central role in memory formation and relational 
memory binding (Hannula and Ranganath, 2008). Patients with schizophrenia have a 
deficit in verbal learning and memory (Hannula and Ranganath, 2008, Lepage et al., 
2015, Schaefer et al., 2013) and altered hippocampal function during memory 
processing (Hannula and Ranganath, 2008, Ragland et al., 2015), leading to the 
suggestion that memory deficits and associated altered brain function may be 
potential neurocognitive markers of schizophrenia (Lepage et al., 2015). Impairment 
in learning and memory, specifically dose-related (Curran et al., 2002) impairment in 
verbal learning (Curran et al., 2002, Henquet et al., 2006, Ranganathan and D'Souza, 
2006) that cannot be accounted for by effects on attention (Curran et al., 2002, 
Ranganathan and D'Souza, 2006), is also one of the most prominent acute cognitive 
effects of THC in man that persists in chronic users (Schoeler and Bhattacharyya, 
2013, Schoeler et al., 2016a, Solowij et al., 2002). Patients with schizophrenia are 
more vulnerable to dose-related verbal learning impairments under the influence of 
THC compared to healthy individuals (D'Souza et al., 2005). The hippocampus has a 
high density of the type 1 central cannabinoid receptors (Eggan and Lewis, 2007, 
Elphick and Egertova, 2001), which are the main central target of THC and animal 
studies show that the effect of THC on learning correlate with its effect on 
hippocampal neuronal firing (Heyser et al., 1993, Robbe et al., 2006). Hence, one 
may predict that increased hippocampal activity may also underlie sensitivity to the 
psychotomimetic effects of THC. This hypothesis has not been tested before. The 
only previous study that investigated neurophysiological differences between those 
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who develop transient psychotic symptoms (TP group) and those that do not (NP 
group) in response to experimental THC challenge employed a cognitive 
(psychomotor control) task that does not normally engage the hippocampal region 
(Atakan et al., 2013).   
 
On the other hand, neuroimaging studies in healthy individuals have demonstrated 
that THC disrupts brain activity in regions associated with memory such as the medial 
temporal and prefrontal cortices as well functional connectivity between them during 
memory processing (Bhattacharyya et al., 2012a, Bhattacharyya et al., 2015b, 
Bhattacharyya et al., 2009) and other cognitive tasks (Bhattacharyya et al., 2012b, 
Bhattacharyya et al., 2015b, Bhattacharyya et al., 2010). In the present study, we 
therefore re-analysed previously reported data acquired employing a verbal memory 
paradigm that engages the hippocampus (Bhattacharyya et al., 2012a) to examine 
whether differences in brain activation during task performance would differentiate 
those healthy individuals who experience transient psychotic (TP) symptoms from 
those who do not (NP), following an acute challenge with THC. Brain activation was 
indexed using blood oxygen level dependent (BOLD) haemodynamic response 
measured using fMRI while participants performed a verbal paired associates learning 
task. We predicted that when performing the task under placebo conditions, 
individuals who were sensitive to the psychotomimetic effects of THC (TP PLB) 
would show greater hippocampal activation than those who were not (NP PLB). We 
then tested the hypothesis that this difference in brain activation under the placebo 
condition between TP and NP groups would be directly associated with the magnitude 
of THC-induced psychotomimetic effects in the same individuals. Finally, we 
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hypothesized that THC administration would modulate brain activation differently in 
the TP and NP groups, reflecting the different symptomatic effects.  
Furthermore, we carried out exploratory analysis to investigate whether the difference 
in neurophysiological response between TP and NP under placebo condition was a 
specific biomarker for THC-induced psychotomimetic effects as opposed to acute 
effects of THC on other symptoms such as anxiety, by testing whether brain activity 
differences between individuals who experienced acute anxiety (TA PLB) under THC 
versus those who did not experience anxiety (NA PLB) were in different brain regions 
compared to differences between ‘TP PLB’ and ‘NP PLB’ groups.  
 
 
Methods and Materials 
Using an established protocol (Bhattacharyya et al., 2012a, Bhattacharyya et al., 
2012b, Bhattacharyya et al., 2009), 36 healthy, occasional cannabis user male 
participants attended two sessions at least one month apart when they were given 
an identical capsule to be taken orally, containing either 10mg of THC or placebo 
using a pseudo-randomised, double-blind, repeated-measures, within-subject 
crossover design and a counterbalanced order of drug administration. Following 
administration, the subjects were required to complete a verbal paired associate 
learning task (Bhattacharyya et al., 2009) while their brain activity was measured 
using fMRI. Methods and study participants are described in detail in 
Supplementary Methods. While we have previously reported the effects of THC 
and its genetic moderation at a group level (Bhattacharyya et al., 2012a, 
Bhattacharyya et al., 2009), the present study focuses on brain function 
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differences between those individuals who were sensitive to the psychotomimetic 
effects of THC compared to those who were not (see details below). 
Participants were right-handed, English-speaking males, without a personal or family 
history of mental illness in first-degree relatives, mean age of 25.97±5.58 and mean 
National adult reading test (NART) score of 97.7±6. Alcohol, cannabis and other 
illicit drug use was assessed using the Addiction Severity index (McLellan et al., 
1980). They had used cannabis upto 25 times in their lifetime, drank less than 21 
units/week of alcohol and had minimal exposure to other illicit drugs (see 
Supplementary Table 1). Participants were asked to abstain from all recreational 
drugs for the duration of the study and one month prior to it. Each participant passed a 
negative urine drug screen on the morning of each session for opiates, cocaine, 
amphetamines, benzodiazepines and THC to ensure that no traces of these drugs were 
in their systems. Psychological assessments (to assess mental state) were conducted 
and blood samples (to assess drug levels) were taken prior to and 1, 2, and 3 hours 
after drug administration. MRI scans were performed 1 hour after ingestion of the 
drug. 
Psychotomimetic effects of THC were measured by an experienced clinical researcher 
using the positive and negative syndrome scale (PANSS) (Kay et al., 1987). State-
trait anxiety inventory- state (STAI) (Spielberger, 1983) and the analogue intoxication 
scale (AIS) (Mathew et al., 1992) were used to measure anxiety and level of 
intoxication respectively. Psychological effects peaked 2 hours after THC 
administration, and hence ratings at this time point were used to compare the TP and 
NP groups. 
Classification of participants on the basis of sensitivity to THC 
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For the purpose of this investigation, we established a priori criteria (also see 
Supplementary Methods) to define transient psychosis induced by THC, which were 
used to classify the participants into those who experienced transient 
psychotomimetic effects (TP) and those who did not (NP). Participants were 
identified as having experienced transient psychotic symptoms and allocated to the 
TP group if they scored at least 3 or more on any of the PANSS positive subscale 
items that measured psychotic symptoms (Delusions, Hallucinations, Suspiciousness/ 
Persecution) during any of the time-points when ratings were obtained following 
THC administration (Atakan et al., 2013). Each item of PANSS is scored on a 7-
point Likert scale, with a score of 1 denoting that the item being measured is 
“absent”, a score of 2 denoting that it is “minimal” (indicating “questionable or 
subtle or suspect pathology” and a score of 3 denoting “mild” (indicating “a 
symptom whose presence is clearly established but not pronounced”). Higher scores 
on each of these items indicate greater severity. A score of 3 was used as the cut-off 
as it 3 denotes “mild” severity, indicating “a symptom whose presence is clearly 
established but not pronounced”, and is the threshold used in the clinical setting to 
indicate clear, unambiguous presence of a psychotic symptom (Kay et al., 1987). 
Psychotic symptoms scored in these participants were otherwise comparable to that 
observed in a clinical situation except for the transient nature of psychotic symptoms 
observed under the experimental THC challenge condition. For our exploratory 
analyses, participants were classified into those who experienced transient anxiety 
(TA) and those who did not (NA) under the influence of THC on the basis of a 
greater (TA) or lesser (NA) than 4-point change in their STAI (when baseline 
STAI score was deducted from their peak post-THC STAI score) in response to 
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THC administration. This cut-off was determined using the Reliable Change Index 
(Jacobson and Truax, 1991).  
 
Image acquisition 
fMRI scans were acquired using a 1.5 tesla scanner (see supplementary methods). 
During fMRI acquisition, subjects completed a verbal paired associate learning 
task (Bhattacharyya et al., 2009), which comprised encoding, recall and baseline 
conditions. For the encoding condition, subjects were required to indicate 
whether visually presented word pairs were related in terms of their meaning, 
while during a subsequent recall condition, they were presented with one word 
from each pair presented before and were required to recall the missing word that 
had been previously associated with the word. During the baseline condition, 
subjects were presented with word-pairs with identical or different fonts and they 
were asked to indicate if the fonts were identical. For each of the conditions, 8 
stimuli pairs were presented sequentially across 4 blocks. Recall score was used as a 
measure of task performance during the memory task. Analysis of performance data 
suggested a ceiling effect by the 3rd block (Supplementary Figure 1) and hence only 
data from the first 3 blocks were analysed.  
 
Data analysis 
Psychological ratings and memory task performance were analyzed using SPSS 
version 22. Socio-demographic characteristics (such as age, NART score and number 
of years in education) and task performance (recall score) of the groups (TP vs NP 
and TA vs NA) were compared using two-sample t-tests while symptom data at 2 
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hours after THC and placebo administration were compared using Mann-whitney U 
tests as they did not fit normal distribution.  
 
Imaging data were pre-processed and analysed (following previously reported 
approaches) using XBAMv4.1 (http://www.brainmap.co.uk), a non-parametric 
image analysis programme that minimises assumptions about the distribution of 
the data, which is important in fMRI where the data may not follow a Gaussian 
distribution(Thirion et al., 2007) (see Supplementary Methods). 
For each drug condition, we contrasted each of the active (encoding or recall) 
conditions of the verbal memory task against the baseline (fonts) condition at the 
individual subject level to generate contrast of interest map (‘encoding minus 
baseline’ and for ‘recall minus baseline’ conditions) for each subject, which were 
used for subsequent group-level analyses (TP vs NP and TA vs NA).  
To investigate our primary hypothesis that ‘TP PLB’ group would show greater 
hippocampal activation compared to the ‘NP PLB’ group, analysis of variance 
compared the ‘TP PLB’ group and ‘NP PLB’ during the placebo condition in order to 
assess differences in functional activation during the contrast of interest (for 
‘encoding minus baseline’ and for ‘recall minus baseline’ conditions, henceforth 
referred to as ‘encoding’ and ‘recall’ respectively unless otherwise specified) in the 
absence of THC. To test the robustness of these group differences in activation and 
whether they were driven by outliers, we carried out a ‘leave one subject out’ (LOSO) 
analysis, which involved repeating the ANOVA with a different subject from the TP 
group being left out on each repeat. A total of 14 repeat ANOVAs were carried out, 
once with each of the 14 ‘TP PLB’ subjects being left out. We then carried out 
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exploratory analyses to examine whether these brain activation differences during the 
encoding and recall conditions were specific to the sub-groups classified according to 
sensitivity to the psychotomimetic effects of THC (‘TP PLB’ vs ‘NP PLB’) or were 
similar to that between subgroups classified based on sensitivity to anxiogenic effects 
of THC (‘TA PLB’ vs ‘NA PLB’). One-way analysis of variance compared task-
related brain activation differences (during encoding and recall conditions) between 
the ‘TA PLB’ and ‘NA PLB’ groups under the placebo condition to examine whether 
similar group differences exist between ‘TA PLB’ and ‘NA PLB’ groups as between 
‘TP PLB’ and ‘NP PLB’ groups. To test our hypothesis that THC administration 
would modulate brain activation differently in the TP and NP groups, further, 
comparisons (using 2-way ANOVA) were then made between the drug given, TP and 
NP groups and the interaction of effects between them. Statistical values from 
differentially activated brain clusters (mean of all voxels in the cluster) were used to 
identify correlation with behavioural data to test our hypothesis that difference in 
brain activation under the placebo condition between TP and NP groups would be 
directly associated with the magnitude of THC-induced psychotomimetic effects in 
the same individuals. A similar approach was employed to compare ‘TA PLB’ and 
‘NA PLB’ groups. 
 
 
Results 
Symptomatic and behavioural differences between TP and NP  
 
Of the 36 subjects who participated in the study, 14 satisfied our pre-defined 
criteria on the basis of PANSS ratings following THC administration to be 
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classified to the TP group, whilst the remaining 22 subjects formed the NP group. 
These two groups were not significantly different in terms of their socio-
demographic characteristics and estimated pre-morbid IQ (p>0.5) (Table 1) or in 
terms of symptoms experienced under the placebo condition (Mann-Whitney U-
tests p>0.4; Figure 1; eTable 2). However, 2 hours after the administration of 
THC, the ‘TP THC’ group scored significantly higher on both the STAI 
(p=0.008) and AIS  (p=0.001) ratings (Figure 1; Supplementary Table 2). As 
expected, following THC administration, the ‘TP THC’ group showed marked 
increases in all PANSS subscale scores (Figure 1) which were significantly 
higher than the NP group for all of the PANSS subscales (Mann-Whitney U-tests; 
all p<0.001; Supplementary Table 2). Both the TP (‘TP THC’ and ‘TP PLB’) and 
NP (‘NP THC’ and ‘NP PLB’) groups showed similar total recall scores under 
both THC (t-tests; p= 0.85) and placebo conditions (p=0.22) (Supplementary 
Table 2). 
Of the total sample, 18 participants were assigned to the TA group and 18 were 
assigned to the NA group based on their STAI ratings following THC 
administration. T h e  t w o  g r o u p s  were well matched on age and years of 
education, however there was a significant difference between NART-IQ scores 
between TA and NA groups (p=0.04; Table 1). The ‘TA THC’ group had higher 
STAI scores compared to the ‘NA THC’ group following THC administration 
(p=0.016; Supplementary Table 2). However, they were not significantly different 
(p=0.18) in terms of the severity of transient psychotic symptoms (PANSS-Positive 
subscale) induced by THC. Both groups also showed similar total recall scores 
under both placebo and THC (Supplementary Table 2).  
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Of the 14 TP participants, 8 were also in the TA group based on their anxiety ratings 
and 6 were in the NA group. Of the 22 NP participants, 10 were in the TA and 12 in 
the NA group. There was a positive correlation (0.41, p=0.01) between transient 
psychotic symptoms (PANSS-Positive subscale) and anxiety (STAI) measured 2 
hours after administration of THC. 
 
Brain regions engaged by the verbal memory task in all individuals 
 
As expected, during both the encoding and recall conditions in all study participants, 
the verbal memory task was associated with engagement of brain regions previously 
implicated in memory processing, particularly the prefrontal and medial temporal 
cortices (encoding: Supplementary Table 3A; Supplementary Figure 2A; and recall: 
Supplementary Table 3B; Supplementary Figure 2B).  
 
Differences in activation between the ‘TP PLB’ and ‘NP PLB’ groups under placebo 
 
Investigation of our hypothesis that ‘TP PLB’ group would show greater hippocampal 
activation compared to the ‘NP PLB’ group showed that during the encoding 
condition, there was greater engagement of the left hippocampus, left anterior 
cingulate (ACC) and right superior temporal gyrus  (STG) (p<0.001, corrected for <1 
false positive cluster) in the ‘TP PLB’ group than the ‘NP PLB’ group, whereas the 
converse was true in the cerebellum bilaterally (Figure 2; Supplementary Table 4). 
Left hippocampal engagement remained significantly different between the ‘TP PLB’ 
and ‘NP PLB’ groups across all repeats of the leave one subject out (LOSO) analysis 
(which involved repeating the ANOVA with a different subject from the ‘TP PLB’ 
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group being left out on each repeat), whereas the clusters of activation in the STG and 
ACC did not consistently survive this analysis. As there was a direct correlation 
between the transient psychotic symptoms and anxiety induced following THC 
administration, post hoc, we compared the ‘TP PLB’ and ‘NP PLB’ groups during the 
encoding condition under placebo after controlling for the severity of anxiety 
symptoms induced under THC. This did not change the pattern and direction of 
results (data not shown, but available from the authors on request), particularly the 
difference in left hippocampal engagement between the ‘TP PLB’ and ‘NP PLB’ 
groups.     
 
In order to examine whether the group difference in activation between the ‘TP PLB’ 
and ‘NP PLB’ groups truly represented a marker of sensitivity to the psychotomimetic 
effects of THC, we then tested whether activation in these regions under placebo 
condition was directly related to the severity of transient psychotic symptoms induced 
by THC in these individuals. Engagement of the left hippocampus under placebo 
condition showed a non-linear correlation with the increase in the severity of 
psychotic symptoms following administration of THC (spearman’s rho = 0.44, 
p=0.008; Figure 2D).  
 
During the recall condition, significant between-group differences (‘TP PLB’ vs ‘NP 
PLB’’) in activation were observed in the left medial frontal, right middle temporal 
gyrus (MTG) and anterior lobe of cerebellum, where the ‘TP PLB’ group showed 
greater engagement relative to the ‘NP PLB’ group, whereas the converse applied in 
the left inferior parietal lobule, the precentral gyrus bilaterally, the precuneus and 
cingulate gyrus on the right side and the posterior lobe of the cerebellum 
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(Supplementary Figure 3 & Supplementary Table 4). Group (‘TP PLB’ vs ‘NP PLB’) 
differences in activation in these regions did not always survive the LOSO analysis 
and were not investigated further. 
 
 
Specificity of brain activation differences between the ‘TP PLB’ and ‘NP PLB’ 
groups under placebo 
 
Exploratory one-way analysis of variance revealed significant differences in task-
related activation between the ‘TA PLB’ and ‘NA PLB’ groups under the placebo 
condition during both the encoding (Supplementary Table 5; Supplementary Figure 4) 
and the recall (Supplementary Table 5; Supplementary Figure 5) conditions. 
However, these regions did not overlap with those that were differentially activated 
on contrasting the ‘TP PLB’ and ‘NP PLB’ groups.  
 
Differences in activation between the TP and NP groups under THC 
 
Investigation of our hypothesis that THC administration would modulate brain 
activation differently in the TP and NP groups, reflecting the different 
symptomatic effects with two-way ANOVA [Group (TP vs NP) by drug (THC vs 
Placebo)] revealed significant differences in the effect of THC on activation in 
the two groups in a number of areas during the encoding but not the recall 
condition (Figure 3; Supplementary Table 4). Under placebo during the encoding 
condition, there was greater engagement of the right middle frontal gyrus (MFG) 
extending to the precentral gyrus and in the left cingulate gyrus and cerebellum in 
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the ‘TP PLB’ group relative to the ‘NP PLB’ group. However, under the THC 
condition there was a reversal of engagement of these regions: THC attenuated 
their activation in the ‘TP THC’ group but augmented it in the ‘NP THC’ group, 
relative to placebo. The THC-induced change in activation of the right MFG 
inversely correlated with increase in the severity of psychotic symptoms 
following THC (spearman’s rho = -0.6, p=<0.001; Figure 3C). There was no 
significant group (TP vs NP) by drug (THC vs Placebo) interaction in the left 
hippocampus where there was a difference between the ‘TP PLB’ and ‘NP PLB’ 
groups under placebo condition, nor was a similar difference observed between 
‘TP THC’ and ‘NP THC’ groups under THC alone. 
 
Discussion  
Here we investigated whether differences in hippocampal activation measured using 
BOLD fMRI under placebo conditions may distinguish between healthy males who 
are sensitive to the psychotomimetic effects of THC from those who are not. The 
results suggest that altered activation in the left hippocampus an area implicated in 
both normal memory processing and the neuropathology of psychosis, differentiated 
those who experience transient psychotic symptoms following a single dose of THC 
from those who do not.  
 
These differences were not simply a result of differential levels of task performance in 
these two groups, nor were they related to group differences in socio-demographic 
characteristics or psychological ratings at the time the neuroimaging data were 
acquired. As predicted, increased encoding-related engagement of the left 
hippocampus, a region critical for encoding (Eichenbaum et al., 2007), differentiated 
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the THC-sensitive group from those not sensitive to its psychotomimetic effects. 
Furthermore, left hippocampal engagement which reliably differentiated healthy 
individuals on the basis of their sensitivity to acute psychotomimetic effects of THC, 
was directly correlated with the severity of psychotic symptoms induced under the 
influence of THC, such that the greater the engagement of the left hippocampus under 
the placebo condition, greater was the severity of psychotic symptoms induced by 
THC. This was consistent with our hypothesis that difference in brain activation under 
the placebo condition between TP and NP groups would be directly associated with 
the magnitude of THC-induced psychotomimetic effects in the same individuals. 
Difference in hippocampal engagement distinguished individuals sensitive to the 
psychotomimetic effects of THC but not those who experienced anxiety under THC 
as revealed in exploratory analyses, suggesting the relationship was specific to 
psychotic symptoms. This difference in hippocampal engagement persisted even after 
controlling for the severity of THC-induced anxiety suggesting that difference in 
hippocampal activation under placebo condition between the ‘TP PLB’ and ‘NP PLB’ 
individuals was not a marker of differential sensitivity to THC-induced anxiety in the 
same individuals. Collectively, these findings suggest that increased left hippocampal 
engagement during word encoding may be a marker of sensitivity to the acute 
psychotomimetic effects of THC. This is consistent with evidence of increased resting 
hippocampal regional cerebral blood flow (Allen et al., 2015) in those at high clinical 
risk of psychosis and reduced hippocampal volume in those with established 
schizophrenia (Nelson et al., 1998). However, it is worth noting that it is regular 
rather than acute cannabis use that has been linked to schizophrenia. Hence, while 
altered left hippocampal engagement may be a marker of sensitivity to the acute 
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psychotomimetic effects of THC, it may not necessarily be a marker of sensitivity to 
the development of schizophrenia following regular cannabis use.  
By definition, the TP  and NP groups had different responses to THC in relation to 
their levels of acute psychotic symptoms. Consistent with our hypothesis that THC 
administration would modulate brain activation differently in the TP and NP groups, 
our second major finding was that this difference in psychotic symptom generation 
was associated with a difference in the neurophysiological effects of THC in the two 
groups. There was a significant interaction between drug and group in the middle 
frontal gyrus (MFG), a region involved in the organization of memory (Simons and 
Spiers, 2003). Attenuation of lateral prefrontal activity by THC in our study 
correlated with the increase in psychotic symptoms induced by it, and is consistent 
with a similar attenuation of lateral prefrontal activity(Bhattacharyya et al., 2015a) by 
THC that correlated with the severity of psychotic symptoms(Bhattacharyya et al., 
2015a) induced by it as well as genetic moderation(Bhattacharyya et al., 2014) of the 
effects of THC in this region in the context of a cognitive activation task that engaged 
inhibitory control processes. Altered brain activity in this region has also been shown 
in the context of inhibitory and related motor control tasks in cannabis users both 
under acute THC challenge condition(Weinstein et al., 2008) and in its 
absence(Eldreth et al., 2004, Tapert et al., 2007). The lateral prefrontal cortex is rich 
in CB1 receptors(Elphick and Egertova, 2001), the main target of THC in the 
brain(Pertwee, 2008), and results presented here suggest that the effects of THC in 
this region may be involved in the generation of paranoia under its influence 
consistent with dorsolateral prefrontal hypoactivity reported in schizophrenia 
(Callicott et al., 2000) and role of altered lateral prefrontal activity in the 
pathophysiology of psychotic symptoms in schizophrenia(Shergill et al., 2000).  
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We have previously reported that the normal pattern of medial temporal engagement 
while learning new information is altered by an acute THC challenge (Bhattacharyya 
et al., 2009). The present study extends this by establishing that altered hippocampal 
engagement during a memory task distinguishes those healthy individuals who are 
particularly sensitive to the acute psychotomimetic effects of THC from those who 
are not.  
 
Limitations 
 
The results presented here should be considered preliminary in light of certain 
limitations. An important caveat relates to the generalizability of these results under 
laboratory conditions to the small proportion of real-world cannabis users who may 
be sensitive to the psychotomimetic effects of THC, which may be manifest on a 
continuum from mild transient paranoia to frank schizophreniform disorder. It is 
worth noting that psychotic-like symptoms experienced by participants in this study 
were transient and self-limited unlike those observed in established psychosis, but not 
dissimilar to the transient paranoia experienced by large number of cannabis users. 
We ensured that the psychotic symptoms experienced by participants classified as part 
of the transiently psychotic group were qualitatively similar to overt psychotic 
symptoms such as delusions and hallucinations and not merely a result of behavioural 
disorganization, by setting a cut-off threshold identical to that employed in clinical 
practice. It is also worth noting the present study does not account for other factors 
such as genetic (Bhattacharyya et al., 2012a, Bhattacharyya et al., 2014, Di Forti et 
al., 2012, van Winkel et al., 2011) and personality and familial factors (Henquet et 
al., 2005, McGuire et al., 1995, Stirling et al., 2008) as well as the composition 
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(Bhattacharyya et al., 2010) and dose (Schoeler et al., 2016c) of cannabis that may 
also underlie differential sensitivity to the effects of cannabis. 
It may also be argued that the articulation of verbal responses during the task may 
have resulted in head movement, which would have affected brain activation that in 
turn may have influenced our results. An effect of articulation seems unlikely because 
the findings in our study were obtained from comparisons of repetitions of the same 
condition between groups or between the effects of drugs on the same conditions in 
the two groups. As the verbal responses in these comparisons were identical, even if 
articulation had affected the fMRI signal, it would have had to have a systematically 
different effect between the two groups (TP vs NP) or in the presence of one drug 
versus another. This seems unlikely, as there was no change in the demands on 
articulation between the two groups or between the drug conditions, and there was no 
significant difference in the performance of the task between the groups under the two 
drug conditions. We thus think that it is highly unlikely that head movement due to 
verbal responses during the task significantly affected the results.  
Similarly, one may suggest that expectation or memory of the psychotomimetic 
effects of THC may partly account for the brain activation differences between the TP 
and NP groups. However, this is also unlikely to fully account for these findings, as 
such an effect on brain activation should have been similarly evident on comparison 
of the TA and NA groups, which it was not. Furthermore, because of the very nature 
of this study, individuals with marked psychosis-like effects during previous cannabis 
use may have been less likely to volunteer for such a study, suggesting that any effect 
of expectation or memory of psychotomimetic effects of THC is unlikely to have been 
substantial. It is also worth noting that participants in this study had limited previous 
exposure to cannabis. Hence, even if such an effect had been present, it is likely that 
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this would have been cancelled out on comparison of two groups with minimal 
previous exposure to cannabis (TP vs NP). 
 
It is also important to note that this study cannot establish whether association 
between hippocampal activation and sensitivity to the psychotomimetic effects of 
THC was specific to the use of a verbal paired associate learning task as opposed to 
cognitive paradigms that engage other cognitive processes affected by THC, as we did 
not investigate this. Future systematic investigation in this area may be warranted. 
Finally, the relatively modest sample size of the present cohort should also be noted, 
highlighting the need for independent replication in larger samples. 
 
Collectively, our results suggest altered hippocampal activation may underlie 
sensitivity to the acute psychotomimetic effects of THC under experimental 
conditions in occasional cannabis users. While one may speculate that altered 
hippocampal activation may also predict sensitivity to the onset of psychotic disorders 
or a relapse of psychosis following regular cannabis use, this was not tested here and 
will require further investigation in prospective studies.  
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Figure Legends 
 
Figure 1. Changes in anxiety, intoxication and psychotic symptoms under the THC 
condition  
Line graphs show anxiety (A: state-trait anxiety inventory- state; STAI) and intoxication 
(B: analogue intoxication scale; AIS) ratings for both the transiently psychotic (TP THC) 
and non-psychotic (NP THC) group  recorded before (0 hour) and one, two and three 
hours after drug administration. Line graphs show ratings on positive (C), negative (D), 
general psychopathology (E) subscales and total score (F) of the positive and negative 
syndrome scale (PANSS for both the transiently psychotic group (TP) and non-psychotic 
group (NP) following the administration of THC (TP THC and NP THC) and placebo (TP 
PLB and NP PLB) recorded before (0 hour) and one, two and three hours after drug 
administration. Error-bars represent standard error of the mean.  
Figure 2. Brain activation differences between those sensitive to the psychotomimetic 
effects of THC (TP PLB) versus those who were not (NP PLB) under placebo during the 
encoding condition of the verbal learning task. Brain sections on the left column show 
greater engagement of the left hippocampus (A), left anterior cingulate (B) and right superior 
temporal gyrus (C) in the transiently psychotic (TP PLB) compared to the non-psychotic (NP 
PLB) group during encoding under the placebo condition. Bar charts on the right column 
display the mean brain activation (error bars represent standard error of mean; SEM) values 
(arbitrary units) from the corresponding brain regions.. All results are significant at p<0.008 
(cluster p values corrected to yield <1 false positive cluster). Left side of the brain is shown on 
the left side of the brain images. 
Scatter-plot (D) displays the non-linear correlation between engagement of the left 
hippocampus under placebo condition with the increase in severity of psychotic symptoms 
following administration of THC (spearman’s rho = 0.44, p=0.008).  
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Figure 3. Brain activation differences between those sensitive to the psychotomimetic 
effects of THC (TP) versus those who were not (NP) under THC relative to placebo 
treatment during the encoding condition of the verbal learning task. 
Brain section (A) displays a cluster in the right middle frontal gyrus (MFG) extending to the 
precentral gyrus (cross-hair) and a cluster in the left cingulate, where there was greater 
engagement (shown in bar chart B; mean brain activation and error bars represent standard 
error of mean, SEM; all values in arbitrary units) under placebo treatment in the TP group 
relative to the NP group, which was reversed under THC treatment condition. Left side of the 
brain is shown on the left side of the brain image. 
THC-induced change in activation of the right MFG inversely correlated (scatter-plot C) with 
increase in severity of psychotic symptoms under THC (spearman’s rho = -0.6, p=<0.001). 
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Table 1: Socio-demographic variables 
 
S.D. is standard deviation reported within brackets 
 
 
 Transiently 
psychotic (n=14) 
Non-psychotic 
(n=22) 
p value 
Mean age, years (S.D.) 25.86 (5.14) 26.05 (5.96) 0.92 
Mean NART Score (S.D.) 97.07 (8.32) 98.24 (5.37) 0.65 
Mean years in education (S.D.) 16.58 (4.06) 17.41 (4.40) 0.59 
 Transiently 
anxious (n=18) 
Non-anxious 
(n=18)  
p value 
Mean age, years (S.D.) 26.56 (6.00) 25.39 (5.24) 0.53 
Mean NART Score (S.D.) 100 (4.38) 95.61 (7.70) 0.04 
Mean years in education (S.D.) 16.94 (3.21) 17.28 (5.07) 0.81 
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ABSTRACT 
Background: Cannabis and its main psychoactive ingredient delta-9-
tetrahydrocannibidiol (THC), can induce transient psychotic symptoms in healthy 
individuals and exacerbate them in those with established psychosis. However, 
not everyone experiences these effects, suggesting that certain individuals are 
particularly susceptible. The neural basis of this sensitivity to the 
psychotomimetic effects of THC is unclear.  
Methods: We investigated whether individuals who are sensitive to the 
psychotomimetic effects of THC (TP) under experimental conditions would show 
differential hippocampal activation compared to those who are not (NP). We 
studied 36 healthy males under identical conditions under the influence of 
placebo or THC (10 mg) given orally, on two separate occasions, in a pseudo-
randomised, double-blind, repeated measures, within-subject, cross-over design, 
using psychopathological assessments and functional MRI while they performed 
a verbal learning task. They were classified into those who experienced transient 
psychotic symptoms (TP; n=14) following THC administration and those who did 
not (NP; n=22). Results: Under placebo conditions, there was significantly 
greater engagement of the left hippocampus (p<0.001) in the TP group compared 
to the NP group during verbal encoding, which survived leave-one-out analysis. 
The level of hippocampal activation was directly correlated (spearman’s rho= 
0.44, p=0.008) with the severity of transient psychotic symptoms induced by 
THC. This difference was not present when we compared two subgroups from the 
same sample that were defined by sensitivity to anxiogenic effects of THC.  
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Conclusions: These results suggest that altered hippocampal activation during 
verbal encoding may serve as a marker of sensitivity to the acute 
psychotomimetic effects of THC.  
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Introduction 
Regular cannabis use is associated with a dose-dependent increase in the risk of onset 
(Moore et al., 2007, Zammit et al., 2002) and exacerbation (Patel et al., 2016, 
Schoeler et al., 2016b, Schoeler et al., 2016c, Schoeler et al., 2016d) of psychotic 
disorders such as schizophrenia. Consistent with this, delta-9-tetrahydrocannabinol 
(THC), the main psychoactive ingredient in cannabis has been shown in experimental 
studies to induce transient psychotic symptoms in healthy subjects (Bhattacharyya et 
al., 2015a, Bhattacharyya et al., 2009, D'Souza et al., 2004, Morrison et al., 2011) 
and exacerbate them in schizophrenia patients (D'Souza et al., 2005, Henquet et al., 
2006).  
 
However, there is marked variation in the psychotomimetic and cognitive effects of 
cannabis based on genetic (Bhattacharyya et al., 2012a, Bhattacharyya et al., 2014) 
and personality and familial factors (Di Forti et al., 2012, Henquet et al., 2005, 
McGuire et al., 1995, Stirling et al., 2008, van Winkel et al., 2011) as well as the 
composition of cannabis (Bhattacharyya et al., 2010). Experimental studies in healthy 
individuals suggest that even when given substantial doses of pure THC, not all will 
experience a state of transient psychosis (Atakan et al., 2013, Bhattacharyya et al., 
2010). While this may point towards fundamental neurobiological differences 
between those who are susceptible to the psychotomimetic effects of THC and those 
who are not, it is unclear if this is the case.   
 
Evidence from animal models has led to the hypothesis that the development of 
psychosis may be associated with increased hippocampal activity (Lodge and Grace, 
2007), in turn driving striatal dopaminergic overactivity (Lodge and Grace, 2011). 
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This is consistent with evidence of increased resting hippocampal regional cerebral 
blood flow (Allen et al., 2015) and increased hippocampal activation during memory 
tasks (Valli et al., 2011) in individuals at high risk of developing psychosis (Allen et 
al., 2015). The hippocampus has a central role in memory formation and relational 
memory binding (Hannula and Ranganath, 2008). Patients with schizophrenia have a 
deficit in verbal learning and memory (Hannula and Ranganath, 2008, Lepage et al., 
2015, Schaefer et al., 2013) and altered hippocampal function during memory 
processing (Hannula and Ranganath, 2008, Ragland et al., 2015), leading to the 
suggestion that memory deficits and associated altered brain function may be 
potential neurocognitive markers of schizophrenia (Lepage et al., 2015). Impairment 
in learning and memory, specifically dose-related (Curran et al., 2002) impairment in 
verbal learning (Curran et al., 2002, Henquet et al., 2006, Ranganathan and D'Souza, 
2006) that cannot be accounted for by effects on attention (Curran et al., 2002, 
Ranganathan and D'Souza, 2006), is also one of the most prominent acute cognitive 
effects of THC in man that persists in chronic users (Schoeler and Bhattacharyya, 
2013, Schoeler et al., 2016a, Solowij et al., 2002). Patients with schizophrenia are 
more vulnerable to dose-related verbal learning impairments under the influence of 
THC compared to healthy individuals (D'Souza et al., 2005). The hippocampus has a 
high density of the type 1 central cannabinoid receptors (Eggan and Lewis, 2007, 
Elphick and Egertova, 2001), which are the main central target of THC and animal 
studies show that the effect of THC on learning correlate with its effect on 
hippocampal neuronal firing (Heyser et al., 1993, Robbe et al., 2006). Hence, one 
may predict that increased hippocampal activity may also underlie sensitivity to the 
psychotomimetic effects of THC. This hypothesis has not been tested before. The 
only previous study that investigated neurophysiological differences between those 
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who develop transient psychotic symptoms (TP group) and those that do not (NP 
group) in response to experimental THC challenge employed a cognitive 
(psychomotor control) task that does not normally engage the hippocampal region 
(Atakan et al., 2013).   
 
On the other hand, neuroimaging studies in healthy individuals have demonstrated 
that THC disrupts brain activity in regions associated with memory such as the medial 
temporal and prefrontal cortices as well functional connectivity between them during 
memory processing (Bhattacharyya et al., 2012a, Bhattacharyya et al., 2015b, 
Bhattacharyya et al., 2009) and other cognitive tasks (Bhattacharyya et al., 2012b, 
Bhattacharyya et al., 2015b, Bhattacharyya et al., 2010). In the present study, we 
therefore re-analysed previously reported data acquired employing a verbal memory 
paradigm that engages the hippocampus (Bhattacharyya et al., 2012a) to examine 
whether differences in brain activation during task performance would differentiate 
those healthy individuals who experience transient psychotic (TP) symptoms from 
those who do not (NP), following an acute challenge with THC. Brain activation was 
indexed using blood oxygen level dependent (BOLD) haemodynamic response 
measured using fMRI while participants performed a verbal paired associates learning 
task. We predicted that when performing the task under placebo conditions, 
individuals who were sensitive to the psychotomimetic effects of THC (TP PLB) 
would show greater hippocampal activation than those who were not (NP PLB). We 
then tested the hypothesis that this difference in brain activation under the placebo 
condition between TP and NP groups would be directly associated with the magnitude 
of THC-induced psychotomimetic effects in the same individuals. Finally, we 
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hypothesized that THC administration would modulate brain activation differently in 
the TP and NP groups, reflecting the different symptomatic effects.  
Furthermore, we carried out exploratory analysis to investigate whether the difference 
in neurophysiological response between TP and NP under placebo condition was a 
specific biomarker for THC-induced psychotomimetic effects as opposed to acute 
effects of THC on other symptoms such as anxiety, by testing whether brain activity 
differences between individuals who experienced acute anxiety (TA PLB) under THC 
versus those who did not experience anxiety (NA PLB) were in different brain regions 
compared to differences between ‘TP PLB’ and ‘NP PLB’ groups.  
 
 
Methods and Materials 
Using an established protocol (Bhattacharyya et al., 2012a, Bhattacharyya et al., 
2012b, Bhattacharyya et al., 2009), 36 healthy, occasional cannabis user male 
participants attended two sessions at least one month apart when they were given 
an identical capsule to be taken orally, containing either 10mg of THC or placebo 
using a pseudo-randomised, double-blind, repeated-measures, within-subject 
crossover design and a counterbalanced order of drug administration. Following 
administration, the subjects were required to complete a verbal paired associate 
learning task (Bhattacharyya et al., 2009) while their brain activity was measured 
using fMRI. Methods and study participants are described in detail in 
Supplementary Methods. While we have previously reported the effects of THC 
and its genetic moderation at a group level (Bhattacharyya et al., 2012a, 
Bhattacharyya et al., 2009), the present study focuses on brain function 
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differences between those individuals who were sensitive to the psychotomimetic 
effects of THC compared to those who were not (see details below). 
Participants were right-handed, English-speaking males, without a personal or family 
history of mental illness in first-degree relatives, mean age of 25.97±5.58 and mean 
National adult reading test (NART) score of 97.7±6. Alcohol, cannabis and other 
illicit drug use was assessed using the Addiction Severity index (McLellan et al., 
1980). They had used cannabis upto 25 times in their lifetime, drank less than 21 
units/week of alcohol and had minimal exposure to other illicit drugs (see 
Supplementary Table 1). Participants were asked to abstain from all recreational 
drugs for the duration of the study and one month prior to it. Each participant passed a 
negative urine drug screen on the morning of each session for opiates, cocaine, 
amphetamines, benzodiazepines and THC to ensure that no traces of these drugs were 
in their systems. Psychological assessments (to assess mental state) were conducted 
and blood samples (to assess drug levels) were taken prior to and 1, 2, and 3 hours 
after drug administration. MRI scans were performed 1 hour after ingestion of the 
drug. 
Psychotomimetic effects of THC were measured by an experienced clinical researcher 
using the positive and negative syndrome scale (PANSS) (Kay et al., 1987). State-
trait anxiety inventory- state (STAI) (Spielberger, 1983) and the analogue intoxication 
scale (AIS) (Mathew et al., 1992) were used to measure anxiety and level of 
intoxication respectively. Psychological effects peaked 2 hours after THC 
administration, and hence ratings at this time point were used to compare the TP and 
NP groups. 
Classification of participants on the basis of sensitivity to THC 
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For the purpose of this investigation, we established a priori criteria (also see 
Supplementary Methods) to define transient psychosis induced by THC, which were 
used to classify the participants into those who experienced transient 
psychotomimetic effects (TP) and those who did not (NP). Participants were 
identified as having experienced transient psychotic symptoms and allocated to the 
TP group if they scored at least 3 or more on any of the PANSS positive subscale 
items that measured psychotic symptoms (Delusions, Hallucinations, Suspiciousness/ 
Persecution) during any of the time-points when ratings were obtained following 
THC administration (Atakan et al., 2013). Each item of PANSS is scored on a 7-
point Likert scale, with a score of 1 denoting that the item being measured is 
“absent”, a score of 2 denoting that it is “minimal” (indicating “questionable or 
subtle or suspect pathology” and a score of 3 denoting “mild” (indicating “a 
symptom whose presence is clearly established but not pronounced”). Higher scores 
on each of these items indicate greater severity. A score of 3 was used as the cut-off 
as it 3 denotes “mild” severity, indicating “a symptom whose presence is clearly 
established but not pronounced”, and is the threshold used in the clinical setting to 
indicate clear, unambiguous presence of a psychotic symptom (Kay et al., 1987). 
Psychotic symptoms scored in these participants were otherwise comparable to that 
observed in a clinical situation except for the transient nature of psychotic symptoms 
observed under the experimental THC challenge condition. For our exploratory 
analyses, participants were classified into those who experienced transient anxiety 
(TA) and those who did not (NA) under the influence of THC on the basis of a 
greater (TA) or lesser (NA) than 4-point change in their STAI (when baseline 
STAI score was deducted from their peak post-THC STAI score) in response to 
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THC administration. This cut-off was determined using the Reliable Change Index 
(Jacobson and Truax, 1991).  
 
Image acquisition 
fMRI scans were acquired using a 1.5 tesla scanner (see supplementary methods). 
During fMRI acquisition, subjects completed a verbal paired associate learning 
task (Bhattacharyya et al., 2009), which comprised encoding, recall and baseline 
conditions. For the encoding condition, subjects were required to indicate 
whether visually presented word pairs were related in terms of their meaning, 
while during a subsequent recall condition, they were presented with one word 
from each pair presented before and were required to recall the missing word that 
had been previously associated with the word. During the baseline condition, 
subjects were presented with word-pairs with identical or different fonts and they 
were asked to indicate if the fonts were identical. For each of the conditions, 8 
stimuli pairs were presented sequentially across 4 blocks. Recall score was used as a 
measure of task performance during the memory task. Analysis of performance data 
suggested a ceiling effect by the 3rd block (Supplementary Figure 1) and hence only 
data from the first 3 blocks were analysed.  
 
Data analysis 
Psychological ratings and memory task performance were analyzed using SPSS 
version 22. Socio-demographic characteristics (such as age, NART score and number 
of years in education) and task performance (recall score) of the groups (TP vs NP 
and TA vs NA) were compared using two-sample t-tests while symptom data at 2 
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hours after THC and placebo administration were compared using Mann-whitney U 
tests as they did not fit normal distribution.  
 
Imaging data were pre-processed and analysed (following previously reported 
approaches) using XBAMv4.1 (http://www.brainmap.co.uk), a non-parametric 
image analysis programme that minimises assumptions about the distribution of 
the data, which is important in fMRI where the data may not follow a Gaussian 
distribution(Thirion et al., 2007) (see Supplementary Methods). 
For each drug condition, we contrasted each of the active (encoding or recall) 
conditions of the verbal memory task against the baseline (fonts) condition at the 
individual subject level to generate contrast of interest map (‘encoding minus 
baseline’ and for ‘recall minus baseline’ conditions) for each subject, which were 
used for subsequent group-level analyses (TP vs NP and TA vs NA).  
To investigate our primary hypothesis that ‘TP PLB’ group would show greater 
hippocampal activation compared to the ‘NP PLB’ group, analysis of variance 
compared the ‘TP PLB’ group and ‘NP PLB’ during the placebo condition in order to 
assess differences in functional activation during the contrast of interest (for 
‘encoding minus baseline’ and for ‘recall minus baseline’ conditions, henceforth 
referred to as ‘encoding’ and ‘recall’ respectively unless otherwise specified) in the 
absence of THC. To test the robustness of these group differences in activation and 
whether they were driven by outliers, we carried out a ‘leave one subject out’ (LOSO) 
analysis, which involved repeating the ANOVA with a different subject from the TP 
group being left out on each repeat. A total of 14 repeat ANOVAs were carried out, 
once with each of the 14 ‘TP PLB’ subjects being left out. We then carried out 
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exploratory analyses to examine whether these brain activation differences during the 
encoding and recall conditions were specific to the sub-groups classified according to 
sensitivity to the psychotomimetic effects of THC (‘TP PLB’ vs ‘NP PLB’) or were 
similar to that between subgroups classified based on sensitivity to anxiogenic effects 
of THC (‘TA PLB’ vs ‘NA PLB’). One-way analysis of variance compared task-
related brain activation differences (during encoding and recall conditions) between 
the ‘TA PLB’ and ‘NA PLB’ groups under the placebo condition to examine whether 
similar group differences exist between ‘TA PLB’ and ‘NA PLB’ groups as between 
‘TP PLB’ and ‘NP PLB’ groups. To test our hypothesis that THC administration 
would modulate brain activation differently in the TP and NP groups, further, 
comparisons (using 2-way ANOVA) were then made between the drug given, TP and 
NP groups and the interaction of effects between them. Statistical values from 
differentially activated brain clusters (mean of all voxels in the cluster) were used to 
identify correlation with behavioural data to test our hypothesis that difference in 
brain activation under the placebo condition between TP and NP groups would be 
directly associated with the magnitude of THC-induced psychotomimetic effects in 
the same individuals. A similar approach was employed to compare ‘TA PLB’ and 
‘NA PLB’ groups. 
 
 
Results 
Symptomatic and behavioural differences between TP and NP  
 
Of the 36 subjects who participated in the study, 14 satisfied our pre-defined 
criteria on the basis of PANSS ratings following THC administration to be 
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classified to the TP group, whilst the remaining 22 subjects formed the NP group. 
These two groups were not significantly different in terms of their socio-
demographic characteristics and estimated pre-morbid IQ (p>0.5) (Table 1) or in 
terms of symptoms experienced under the placebo condition (Mann-Whitney U-
tests p>0.4; Figure 1; eTable 2). However, 2 hours after the administration of 
THC, the ‘TP THC’ group scored significantly higher on both the STAI 
(p=0.008) and AIS  (p=0.001) ratings (Figure 1; Supplementary Table 2). As 
expected, following THC administration, the ‘TP THC’ group showed marked 
increases in all PANSS subscale scores (Figure 1) which were significantly 
higher than the NP group for all of the PANSS subscales (Mann-Whitney U-tests; 
all p<0.001; Supplementary Table 2). Both the TP (‘TP THC’ and ‘TP PLB’) and 
NP (‘NP THC’ and ‘NP PLB’) groups showed similar total recall scores under 
both THC (t-tests; p= 0.85) and placebo conditions (p=0.22) (Supplementary 
Table 2). 
Of the total sample, 18 participants were assigned to the TA group and 18 were 
assigned to the NA group based on their STAI ratings following THC 
administration. T h e  t w o  g r o u p s  were well matched on age and years of 
education, however there was a significant difference between NART-IQ scores 
between TA and NA groups (p=0.04; Table 1). The ‘TA THC’ group had higher 
STAI scores compared to the ‘NA THC’ group following THC administration 
(p=0.016; Supplementary Table 2). However, they were not significantly different 
(p=0.18) in terms of the severity of transient psychotic symptoms (PANSS-Positive 
subscale) induced by THC. Both groups also showed similar total recall scores 
under both placebo and THC (Supplementary Table 2).  
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Of the 14 TP participants, 8 were also in the TA group based on their anxiety ratings 
and 6 were in the NA group. Of the 22 NP participants, 10 were in the TA and 12 in 
the NA group. There was a positive correlation (0.41, p=0.01) between transient 
psychotic symptoms (PANSS-Positive subscale) and anxiety (STAI) measured 2 
hours after administration of THC. 
 
Brain regions engaged by the verbal memory task in all individuals 
 
As expected, during both the encoding and recall conditions in all study participants, 
the verbal memory task was associated with engagement of brain regions previously 
implicated in memory processing, particularly the prefrontal and medial temporal 
cortices (encoding: Supplementary Table 3A; Supplementary Figure 2A; and recall: 
Supplementary Table 3B; Supplementary Figure 2B).  
 
Differences in activation between the ‘TP PLB’ and ‘NP PLB’ groups under placebo 
 
Investigation of our hypothesis that ‘TP PLB’ group would show greater hippocampal 
activation compared to the ‘NP PLB’ group showed that during the encoding 
condition, there was greater engagement of the left hippocampus, left anterior 
cingulate (ACC) and right superior temporal gyrus  (STG) (p<0.001, corrected for <1 
false positive cluster) in the ‘TP PLB’ group than the ‘NP PLB’ group, whereas the 
converse was true in the cerebellum bilaterally (Figure 2; Supplementary Table 4). 
Left hippocampal engagement remained significantly different between the ‘TP PLB’ 
and ‘NP PLB’ groups across all repeats of the leave one subject out (LOSO) analysis 
(which involved repeating the ANOVA with a different subject from the ‘TP PLB’ 
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group being left out on each repeat), whereas the clusters of activation in the STG and 
ACC did not consistently survive this analysis. As there was a direct correlation 
between the transient psychotic symptoms and anxiety induced following THC 
administration, post hoc, we compared the ‘TP PLB’ and ‘NP PLB’ groups during the 
encoding condition under placebo after controlling for the severity of anxiety 
symptoms induced under THC. This did not change the pattern and direction of 
results (data not shown, but available from the authors on request), particularly the 
difference in left hippocampal engagement between the ‘TP PLB’ and ‘NP PLB’ 
groups.     
 
In order to examine whether the group difference in activation between the ‘TP PLB’ 
and ‘NP PLB’ groups truly represented a marker of sensitivity to the psychotomimetic 
effects of THC, we then tested whether activation in these regions under placebo 
condition was directly related to the severity of transient psychotic symptoms induced 
by THC in these individuals. Engagement of the left hippocampus under placebo 
condition showed a non-linear correlation with the increase in the severity of 
psychotic symptoms following administration of THC (spearman’s rho = 0.44, 
p=0.008; Figure 2D).  
 
During the recall condition, significant between-group differences (‘TP PLB’ vs ‘NP 
PLB’’) in activation were observed in the left medial frontal, right middle temporal 
gyrus (MTG) and anterior lobe of cerebellum, where the ‘TP PLB’ group showed 
greater engagement relative to the ‘NP PLB’ group, whereas the converse applied in 
the left inferior parietal lobule, the precentral gyrus bilaterally, the precuneus and 
cingulate gyrus on the right side and the posterior lobe of the cerebellum 
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(Supplementary Figure 3 & Supplementary Table 4). Group (‘TP PLB’ vs ‘NP PLB’) 
differences in activation in these regions did not always survive the LOSO analysis 
and were not investigated further. 
 
 
Specificity of brain activation differences between the ‘TP PLB’ and ‘NP PLB’ 
groups under placebo 
 
Exploratory one-way analysis of variance revealed significant differences in task-
related activation between the ‘TA PLB’ and ‘NA PLB’ groups under the placebo 
condition during both the encoding (Supplementary Table 5; Supplementary Figure 4) 
and the recall (Supplementary Table 5; Supplementary Figure 5) conditions. 
However, these regions did not overlap with those that were differentially activated 
on contrasting the ‘TP PLB’ and ‘NP PLB’ groups.  
 
Differences in activation between the TP and NP groups under THC 
 
Investigation of our hypothesis that THC administration would modulate brain 
activation differently in the TP and NP groups, reflecting the different 
symptomatic effects with two-way ANOVA [Group (TP vs NP) by drug (THC vs 
Placebo)] revealed significant differences in the effect of THC on activation in 
the two groups in a number of areas during the encoding but not the recall 
condition (Figure 3; Supplementary Table 4). Under placebo during the encoding 
condition, there was greater engagement of the right middle frontal gyrus (MFG) 
extending to the precentral gyrus and in the left cingulate gyrus and cerebellum in 
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the ‘TP PLB’ group relative to the ‘NP PLB’ group. However, under the THC 
condition there was a reversal of engagement of these regions: THC attenuated 
their activation in the ‘TP THC’ group but augmented it in the ‘NP THC’ group, 
relative to placebo. The THC-induced change in activation of the right MFG 
inversely correlated with increase in the severity of psychotic symptoms 
following THC (spearman’s rho = -0.6, p=<0.001; Figure 3C). There was no 
significant group (TP vs NP) by drug (THC vs Placebo) interaction in the left 
hippocampus where there was a difference between the ‘TP PLB’ and ‘NP PLB’ 
groups under placebo condition, nor was a similar difference observed between 
‘TP THC’ and ‘NP THC’ groups under THC alone.  
 
Discussion  
Here we investigated whether differences in hippocampal activation measured using 
BOLD fMRI under placebo conditions may distinguish between healthy males who 
are sensitive to the psychotomimetic effects of THC from those who are not. The 
results suggest that altered activation in the left hippocampus an area implicated in 
both normal memory processing and the neuropathology of psychosis, differentiated 
those who experience transient psychotic symptoms following a single dose of THC 
from those who do not.  
 
These differences were not simply a result of differential levels of task performance in 
these two groups, nor were they related to group differences in socio-demographic 
characteristics or psychological ratings at the time the neuroimaging data were 
acquired. As predicted, increased encoding-related engagement of the left 
hippocampus, a region critical for encoding (Eichenbaum et al., 2007), differentiated 
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the THC-sensitive group from those not sensitive to its psychotomimetic effects. 
Furthermore, left hippocampal engagement which reliably differentiated healthy 
individuals on the basis of their sensitivity to acute psychotomimetic effects of THC, 
was directly correlated with the severity of psychotic symptoms induced under the 
influence of THC, such that the greater the engagement of the left hippocampus under 
the placebo condition, greater was the severity of psychotic symptoms induced by 
THC. This was consistent with our hypothesis that difference in brain activation under 
the placebo condition between TP and NP groups would be directly associated with 
the magnitude of THC-induced psychotomimetic effects in the same individuals. 
Difference in hippocampal engagement distinguished individuals sensitive to the 
psychotomimetic effects of THC but not those who experienced anxiety under THC 
as revealed in exploratory analyses, suggesting the relationship was specific to 
psychotic symptoms. This difference in hippocampal engagement persisted even after 
controlling for the severity of THC-induced anxiety suggesting that difference in 
hippocampal activation under placebo condition between the ‘TP PLB’ and ‘NP PLB’ 
individuals was not a marker of differential sensitivity to THC-induced anxiety in the 
same individuals. Collectively, these findings suggest that increased left hippocampal 
engagement during word encoding may be a marker of sensitivity to the acute 
psychotomimetic effects of THC. This is consistent with evidence of increased resting 
hippocampal regional cerebral blood flow (Allen et al., 2015) in those at high clinical 
risk of psychosis and reduced hippocampal volume in those with established 
schizophrenia (Nelson et al., 1998). However, it is worth noting that it is regular 
rather than acute cannabis use that has been linked to schizophrenia. Hence, while 
altered left hippocampal engagement may be a marker of sensitivity to the acute 
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psychotomimetic effects of THC, it may not necessarily be a marker of sensitivity to 
the development of schizophrenia following regular cannabis use.  
By definition, the TP  and NP groups had different responses to THC in relation to 
their levels of acute psychotic symptoms. Consistent with our hypothesis that THC 
administration would modulate brain activation differently in the TP and NP groups, 
our second major finding was that this difference in psychotic symptom generation 
was associated with a difference in the neurophysiological effects of THC in the two 
groups. There was a significant interaction between drug and group in the middle 
frontal gyrus (MFG), a region involved in the organization of memory (Simons and 
Spiers, 2003). Attenuation of lateral prefrontal activity by THC in our study 
correlated with the increase in psychotic symptoms induced by it, and is consistent 
with a similar attenuation of lateral prefrontal activity(Bhattacharyya et al., 2015a) by 
THC that correlated with the severity of psychotic symptoms(Bhattacharyya et al., 
2015a) induced by it as well as genetic moderation(Bhattacharyya et al., 2014) of the 
effects of THC in this region in the context of a cognitive activation task that engaged 
inhibitory control processes. Altered brain activity in this region has also been shown 
in the context of inhibitory and related motor control tasks in cannabis users both 
under acute THC challenge condition(Weinstein et al., 2008) and in its 
absence(Eldreth et al., 2004, Tapert et al., 2007). The lateral prefrontal cortex is rich 
in CB1 receptors(Elphick and Egertova, 2001), the main target of THC in the 
brain(Pertwee, 2008), and results presented here suggest that the effects of THC in 
this region may be involved in the generation of paranoia under its influence 
consistent with dorsolateral prefrontal hypoactivity reported in schizophrenia 
(Callicott et al., 2000) and role of altered lateral prefrontal activity in the 
pathophysiology of psychotic symptoms in schizophrenia(Shergill et al., 2000).  
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We have previously reported that the normal pattern of medial temporal engagement 
while learning new information is altered by an acute THC challenge (Bhattacharyya 
et al., 2009). The present study extends this by establishing that altered hippocampal 
engagement during a memory task distinguishes those healthy individuals who are 
particularly sensitive to the acute psychotomimetic effects of THC from those who 
are not.  
 
Limitations 
 
The results presented here should be considered preliminary in light of certain 
limitations. An important caveat relates to the generalizability of these results under 
laboratory conditions to the small proportion of real-world cannabis users who may 
be sensitive to the psychotomimetic effects of THC, which may be manifest on a 
continuum from mild transient paranoia to frank schizophreniform disorder. It is 
worth noting that psychotic-like symptoms experienced by participants in this study 
were transient and self-limited unlike those observed in established psychosis, but not 
dissimilar to the transient paranoia experienced by large number of cannabis users. 
We ensured that the psychotic symptoms experienced by participants classified as part 
of the transiently psychotic group were qualitatively similar to overt psychotic 
symptoms such as delusions and hallucinations and not merely a result of behavioural 
disorganization, by setting a cut-off threshold identical to that employed in clinical 
practice. It is also worth noting the present study does not account for other factors 
such as genetic (Bhattacharyya et al., 2012a, Bhattacharyya et al., 2014, Di Forti et 
al., 2012, van Winkel et al., 2011) and personality and familial factors (Henquet et 
al., 2005, McGuire et al., 1995, Stirling et al., 2008) as well as the composition 
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(Bhattacharyya et al., 2010) and dose (Schoeler et al., 2016c) of cannabis that may 
also underlie differential sensitivity to the effects of cannabis. 
It may also be argued that the articulation of verbal responses during the task may 
have resulted in head movement, which would have affected brain activation that in 
turn may have influenced our results. An effect of articulation seems unlikely because 
the findings in our study were obtained from comparisons of repetitions of the same 
condition between groups or between the effects of drugs on the same conditions in 
the two groups. As the verbal responses in these comparisons were identical, even if 
articulation had affected the fMRI signal, it would have had to have a systematically 
different effect between the two groups (TP vs NP) or in the presence of one drug 
versus another. This seems unlikely, as there was no change in the demands on 
articulation between the two groups or between the drug conditions, and there was no 
significant difference in the performance of the task between the groups under the two 
drug conditions. We thus think that it is highly unlikely that head movement due to 
verbal responses during the task significantly affected the results.  
Similarly, one may suggest that expectation or memory of the psychotomimetic 
effects of THC may partly account for the brain activation differences between the TP 
and NP groups. However, this is also unlikely to fully account for these findings, as 
such an effect on brain activation should have been similarly evident on comparison 
of the TA and NA groups, which it was not. Furthermore, because of the very nature 
of this study, individuals with marked psychosis-like effects during previous cannabis 
use may have been less likely to volunteer for such a study, suggesting that any effect 
of expectation or memory of psychotomimetic effects of THC is unlikely to have been 
substantial. It is also worth noting that participants in this study had limited previous 
exposure to cannabis. Hence, even if such an effect had been present, it is likely that 
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this would have been cancelled out on comparison of two groups with minimal 
previous exposure to cannabis (TP vs NP). 
 
It is also important to note that this study cannot establish whether association 
between hippocampal activation and sensitivity to the psychotomimetic effects of 
THC was specific to the use of a verbal paired associate learning task as opposed to 
cognitive paradigms that engage other cognitive processes affected by THC, as we did 
not investigate this. Future systematic investigation in this area may be warranted. 
Finally, the relatively modest sample size of the present cohort should also be noted, 
highlighting the need for independent replication in larger samples. 
 
Collectively, our results suggest altered hippocampal activation may underlie 
sensitivity to the acute psychotomimetic effects of THC under experimental 
conditions in occasional cannabis users. While one may speculate that altered 
hippocampal activation may also predict sensitivity to the onset of psychotic disorders 
or a relapse of psychosis following regular cannabis use, this was not tested here and 
will require further investigation in prospective studies.  
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Figure Legends 
 
Figure 1. Changes in anxiety, intoxication and psychotic symptoms under the THC 
condition  
Line graphs show anxiety (A: state-trait anxiety inventory- state; STAI) and intoxication 
(B: analogue intoxication scale; AIS) ratings for both the transiently psychotic (TP THC) 
and non-psychotic (NP THC) group  recorded before (0 hour) and one, two and three 
hours after drug administration. Line graphs show ratings on positive (C), negative (D), 
general psychopathology (E) subscales and total score (F) of the positive and negative 
syndrome scale (PANSS for both the transiently psychotic group (TP) and non-psychotic 
group (NP) following the administration of THC (TP THC and NP THC) and placebo (TP 
PLB and NP PLB) recorded before (0 hour) and one, two and three hours after drug 
administration. Error-bars represent standard error of the mean.  
Figure 2. Brain activation differences between those sensitive to the psychotomimetic 
effects of THC (TP PLB) versus those who were not (NP PLB) under placebo during the 
encoding condition of the verbal learning task. Brain sections on the left column show 
greater engagement of the left hippocampus (A), left anterior cingulate (B) and right superior 
temporal gyrus (C) in the transiently psychotic (TP PLB) compared to the non-psychotic (NP 
PLB) group during encoding under the placebo condition. Bar charts on the right column 
display the mean brain activation (error bars represent standard error of mean; SEM) values 
(arbitrary units) from the corresponding brain regions.. All results are significant at p<0.008 
(cluster p values corrected to yield <1 false positive cluster). Left side of the brain is shown on 
the left side of the brain images. 
Scatter-plot (D) displays the non-linear correlation between engagement of the left 
hippocampus under placebo condition with the increase in severity of psychotic symptoms 
following administration of THC (spearman’s rho = 0.44, p=0.008).  
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Figure 3. Brain activation differences between those sensitive to the psychotomimetic 
effects of THC (TP) versus those who were not (NP) under THC relative to placebo 
treatment during the encoding condition of the verbal learning task. 
Brain section (A) displays a cluster in the right middle frontal gyrus (MFG) extending to the 
precentral gyrus (cross-hair) and a cluster in the left cingulate, where there was greater 
engagement (shown in bar chart B; mean brain activation and error bars represent standard 
error of mean, SEM; all values in arbitrary units) under placebo treatment in the TP group 
relative to the NP group, which was reversed under THC treatment condition. Left side of the 
brain is shown on the left side of the brain image. 
THC-induced change in activation of the right MFG inversely correlated (scatter-plot C) with 
increase in severity of psychotic symptoms under THC (spearman’s rho = -0.6, p=<0.001). 
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Table 1: Socio-demographic variables 
 
S.D. is standard deviation reported within brackets 
 
 
 Transiently 
psychotic (n=14) 
Non-psychotic 
(n=22) 
p value 
Mean age, years (S.D.) 25.86 (5.14) 26.05 (5.96) 0.92 
Mean NART Score (S.D.) 97.07 (8.32) 98.24 (5.37) 0.65 
Mean years in education (S.D.) 16.58 (4.06) 17.41 (4.40) 0.59 
 Transiently 
anxious (n=18) 
Non-anxious 
(n=18)  
p value 
Mean age, years (S.D.) 26.56 (6.00) 25.39 (5.24) 0.53 
Mean NART Score (S.D.) 100 (4.38) 95.61 (7.70) 0.04 
Mean years in education (S.D.) 16.94 (3.21) 17.28 (5.07) 0.81 
A B
Figure 1 Click here to download Figure(s) Figure 1.pdf 
B 
C 
A 
D 
Figure 2 Click here to download Figure(s) Figure 2.pdf 
(A) 
(B) 
(C) 
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Supplementary Methods 
 
The study was conducted in accordance with the declaration of Helsinki and was granted 
ethical approval by the joint South London and Maudsley and IOP NHS research committee. 
All participants gave informed written consent to be part of the study. 
 
Participants  
Out of a total of 39 healthy volunteers who took part in the study, 2 dropped out after the first 
session and another could not continue because of adverse drug reactions, resulting in a final 
sample of 36 healthy volunteers for whom all data was available. All of them were right-
handed English-speaking males. None of them had a lifetime personal or family history (in 
first-degree relatives) of mental illness. History of mental illness was assessed on the basis of 
a standard psychiatric interview by an experienced psychiatrist. The mean age of this sample 
was 25.97±5.58 and they had a mean National adult reading test (NART) score of 97.7±6. 
Use of alcohol, cannabis and other illicit drugs was assessed using the Addiction Severity 
index (McLellan et al., 1980). All of the subjects had used cannabis more than once but upto 
25 times within their lifetime. In addition all of the participants drank less than 21 units/week of 
alcohol and none used any other illicit drugs on a regular basis (eTable 1). Participants were 
asked to abstain from all recreational drugs for the duration of the study and one month prior 
to it.   
 
Experimental design 
Each participant attended two sessions that were separated by at least a month interval. At 
each of these sessions either a single dose of 10mg of THC (approximately 99.6% pure, 
THC-pharm, Frankfurt, Germany) or a placebo (a gelatine capsule matched in weight and 
appearance to the THC capsule) was administered to the subjects employing a double-blind 
design. The order of drug administration was pseudo-randomised to ensure that an equal 
number of participants received either drug at each session. During each of the sessions 
participants were required to complete a paired associate verbal learning task while their 
brain activity (as indexed using blood oxygen level-dependent haemodynamic response; 
BOLD) was measured using functional Magnetic Resonance Imaging (fMRI). 
Prior to these sessions, participants were asked to abstain from smoking for 4 hours, drinking 
alcohol for 24 hours and taking caffeine for the 12 hours before each session. On the night 
before the session all subjects were asked to get at least 6 hours sleep. They ate a 
standardised light breakfast on the morning of the scan after overnight fast. Each participant 
then passed a negative urine drug screen (using immunometric assay kits) on the morning of 
each session for opiates, cocaine, amphetamines, benzodiazepines and THC to ensure that 
no traces of these drugs were in their systems. Each session began (prior to drug 
administration) with psychopathological ratings and a venous blood sample. This blood 
sample was taken via the insertion of an indwelling catheter into a subcutaneous vein of the 
non-dominant forearm of the subject. Psychological ratings and blood samples were 
subsequently repeated 1, 2, and 3 hours after drug administration. Psychological ratings and 
blood sampling were carried out at each of the time points outside the MRI scanner.  
Blood samples from pilot studies demonstrated that the concentration of THC in blood 
plateaued at approximately between 1 and 2 hours after ingestion of the drug giving a stable 
concentration for scans to be conducted. MRI scans were therefore performed starting 1 hour 
after ingestion of the drug and these lasted no longer than 60 minutes. Participants were 
asked to complete a verbal paired associate task lasting about 12.5 minutes while they were 
scanned. This task has previously been useful in fMRI studies investigating the effect of THC 
on verbal memory (Bhattacharyya et al., 2009).  
The Verbal Paired Associate Task 
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The verbal paired associate learning task (Bhattacharyya et al., 2009) consisted of three 
different conditions (encoding, recall and baseline) that were presented sequentially and 
involved visual presentation of stimuli. During the encoding condition participants were 
presented with two words presented visually. To promote encoding, participants were 
required to decide whether these words went well together in terms of their meaning. Their 
answers, either ‘yes’ or ‘no’, were communicated verbally and then noted down by the 
researcher. 
For the recall condition, participants were presented with a single word from one of the pairs 
that had previously been presented in the encoding condition. The missing word from that 
pair was replaced with a question mark. Participants were required to recall and articulate the 
missing word. If the subject could not recall the missing word then they were required to say 
‘pass’. 
During the baseline condition, participants were presented with pairs of words printed with 
identical or different fonts. These words were different to those that had been presented 
during the encoding and recall conditions and these word pairs were not repeated across 
baseline blocks. This ensured that learning was kept to a minimum to allow the effect of the 
encoding and recall conditions on neural activity to be identified through comparison of the 
baseline fMRI data with that of the encoding and recall conditions.  
The stimuli for all of the conditions were presented in 40-second blocks. Each of the blocks 
consisted of 8 word pairs and the three conditions were presented sequentially in the same 
order (encoding then recall followed by the baseline condition). The appearance of the 
different word pairs in each block was randomised. Preceding each block, participants were 
reminded of the task for that block by a visual prompt. For the encoding condition this was ‘Do 
these words go well together?’, for the recall condition ‘Which word was associated with this?’ 
and for the baseline condition ‘Are these fonts the same?’. Participants practiced the task 
beforehand using a set of word pairs that were different to those that were then presented 
during the actual fMRI task. Recall scores were recorded as a measure of task performance. 
All words used in this task were drawn from the Medical Research Council Psycholinguistic 
Database (Coltheart, 1981). These are words that have been matched for frequency of use, 
number of letters, familiarity and comprehension (Kučera and Francis, 1967). 
Whilst 4 blocks were presented, only the results from the first 3 blocks are reported here. This 
is because an analysis of task performance revealed that the participants stopped learning 
after the 3 blocks and almost all scored maximally on the recall task.  
Behavioural data acquisition. 
An experienced clinical researcher determined the psychotomimetic effects of THC using the 
Positive and Negative Symptom Scale (PANSS) (Kay et al., 1987). Whilst PANSS is usually 
employed in clinical trials of schizophrenia to rate positive and negative symptoms of 
psychosis as well as other symptoms that are commonly present in those with psychosis 
(general psychopathology), it has also been used in a number of other studies investigating 
the transient psychotomimetic effects of THC (Atakan et al., 2013, Bhattacharyya et al., 
2012a, Bhattacharyya et al., 2012b, Bhattacharyya et al., 2009, D'Souza et al., 2005, 
D'Souza et al., 2004) 
In addition to psychotic symptoms, participants’ state of anxiety and intoxication were 
assessed using the State-Trait Anxiety Inventory (STAI) (Spielberger, 1983)and the Analogue 
Intoxication scale (AIS) (Mathew et al., 1992) respectively. All psychological ratings including 
PANSS were carried out while participants were outside the scanner. 
Classification of participants on the basis of sensitivity to THC 
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For the purpose of this investigation, we established a priori criteria to define transient 
psychosis induced by THC, which were used to classify the participants into those who 
experienced transient psychotomimetic effects (TP) and those who did not (NP). 
Classification was carried out following completion of all data acquisition. Participants were 
identified as having experienced transient psychotic symptoms and allocated to the TP group 
if they scored 3 or more on any of the PANSS positive subscale items that measured 
psychotic symptoms (Delusions, Hallucinations, Suspiciousness/ Persecution) during any of 
the time-points when ratings were obtained following THC administration (Atakan et al., 
2013). Each item of PANSS (Kay et al., 1987) is scored on a 7-point Likert scale, with a 
score of 1 denoting that the item being measured is “absent”, a score of 2 denoting that it is 
“minimal” (indicating “questionable or subtle or suspect pathology” and a score of 3 denoting 
“mild” (indicating “a symptom whose presence is clearly established but not pronounced”). A 
score of 3 was used as the cut-off as this is the threshold used in the clinical setting to 
indicate clear, unambiguous presence of a psychotic symptom (Kay et al., 1987). While 
PANSS does not describe the score of ‘3’ as a threshold, in practice the score of ‘3’ becomes 
a threshold for denoting presence of a symptom, as a score of ‘2’ indicates “Questionable 
pathology; may be at the upper extreme of normal limits”. This is also the scoring threshold 
used in the clinical setting, especially in the context of clinical trials of antipsychotic 
medications to indicate clear, unambiguous presence of these symptoms. For the item 
‘Delusions’, a score of 3 on PANSS refers to “Mild- Presence of one or two delusions that are 
vague, uncrystallized, and not tenaciously held. Delusions do not interfere with thinking, 
social relations, or behavior.” For “Hallucinatory Behaviour”, a score of 3 denotes “Mild- One 
or two clearly formed but infrequent hallucinations, or else a number of vague abnormal 
perceptions which do not result in distortions of thinking or behaviour.”, while for 
“Suspiciousness/ Persecution”, a score of 3 indicates “Mild - Presents a guarded or even 
openly distrustful attitude, but thoughts, interactions and behaviour are minimally affected.” 
Higher scores on each of these items indicate greater severity, while a score of 2 indicates 
“Questionable pathology; may be at the upper extreme of normal limits”. Psychotic 
symptoms scored in these participants were otherwise comparable to that observed in a 
clinical situation except that they were transient in nature, a characteristic that is typical of 
psychotic symptoms observed under the experimental THC challenge condition. In order to 
classify participants between those who experienced transient anxiety (TA) and those who 
did not (NA) under the influence of THC, we used the change in their STAI score over time in 
response to THC administration. Using the Reliable Change Index (Jacobson and Truax, 
1991), we estimated that a 4-point change in STAI score (by deducting baseline STAI score 
from the peak STAI score following THC) would reliably differentiate those who experienced 
anxiety from those who did not experience anxiety following THC administration. Therefore 
any participant, who had over a 4-point change in their STAI, when baseline STAI score 
was deducted from their peak post-THC STAI score, was allocated to the TA group, while 
participants who had less than a 4-point change in their score were in the NA group. 
 
 
Image Acquisition 
Functional MRI images were acquired at the Maudsley hospital using a 1.5 Tesla GE Signa 
system (GE Medical Systems, Milwaukee, WI, USA). During the verbal learning task a 
gradient-echo sequence was used to acquire one hundred and forty-eight T2* weighted 
images at 16 near-axial planes (7 mm thick, inter-slice gap 0.7 mm) parallel to the inter-
commissural (AC-PC) plane with a repetition time (TR) of 5000msec (image volume 
acquisition over 1500msec and period between clustered acquisition of image volumes 3500 
msec), TE of 40 msec and flip angle of 70˚ (FOV 24 x 24 cm and matrix 642). The inter-
stimulus interval was 5000msec. The first 4 (dummy) volumes were discarded to allow for T1 
equilibration effects. During the first 1500msec of the TR images were acquired, for the 
remaining 3500msec the scanner was silent. Each of the visual stimuli that were presented to 
the subject during the verbal learning task were shown to the subject at the beginning of each 
silent period. This allowed for each trial to be performed and verbal response to be recorded 
without the interference of scanner noise. We employed this strategy of using an acquisition 
sequence in which image acquisition was compressed into the initial part of the each TR, 
thereby creating a ‘silent’ period when images were not being acquired and the scanner did 
not produce acoustic noise(Amaro et al., 2002), in order to minimise the potential effect of 
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articulation of verbal responses during the task on brain activation. As verbal responses 
during the task were restricted to these ‘silent’ periods, any head movement associated with 
articulation occurred outside the time when the images were being acquired, reducing the 
likelihood of motion-correlated artifacts(Bullmore et al., 1999a). Furthermore, in the absence 
of acoustic scanner noise, participants did not need to shout their responses. An inversion 
recovery EPI dataset (TR 3000msec, TE 40 msec, flip angle 90˚, near-axial slices, 3mm thick, 
inter-slice gap 0.3mm, in-plane resolution 1.5mm) was acquired to facilitate anatomic 
localization of the functional data. 
Statistical analysis 
 
Image analysis 
XBAM_v4.1 (http://www.brainmap.co.uk), a non-parametric data analysis software package 
developed at the Institute of Psychiatry, Psychology & Neuroscience (King’s College London) 
was used for analysing fMRI data. The non-parametric approach minimises assumptions 
about the distribution of the data. This is important in the analysis of fMRI data because the 
distribution of data may not necessarily follow a normal Gaussian distribution (Brammer et al., 
1997),(Thirion et al., 2007).  By using medians rather than averages as a test statistic, XBAM 
is less sensitive to the effects of outlier values misrepresenting the distribution of the data 
(Hayasaka and Nichols, 2003). The test statistic is computed in this method by standardizing 
for individual differences in residual noise before embarking on a second- level, multi-subject 
testing, using robust permutation-based methods, employing a mixed-effects approach. 
Images were first realigned to correct for head motion (Bullmore et al., 1999a). This involved 
the computation of a 3D volume consisting of the average intensity at each voxel over the 
whole experiment, which was used as a template. The 3D image volume at each time-point 
was then realigned to this template by computing the combination of rotations (around the x, y 
and z axes) and translations (in x, y and z) that maximised the correlation between the image 
intensities of the volume in question and the template 3D volume. The data were then 
smoothed by the application of a 7.2mm full-width-at-half-maximum Gaussian filter to average 
the relative intensities of neighbouring voxels. Activation maps were created for each 
individual by modelling the BOLD signal using 2 gamma-variate functions, peaking at 4 and 8 
seconds to allow for variability in haemodynamic delay. Then, using the constrained BOLD 
effects model, a best fit between the weighted sum of these convolutions and the change 
over time at each voxel was computed (Friman et al., 2003). This reduces the possibility of 
the model-fitting procedure giving rise to mathematically plausible, but physiologically 
implausible results. Following the least squares fitting of this model to the data, the sum of 
squares (SSQ) ratio (ratio of the SSQ of deviations from the mean image intensity due to the 
model component over the whole time series to the SSQ of deviations due to the residuals) 
was estimated for each voxel and this was followed by permutation testing to determine which 
voxels were significantly activated (Bullmore et al., 2001). This addresses the problem 
associated with the use of the F statistic that the residual degrees of freedom are often 
unknown in fMRI time series due to the presence of coloured noise in the signal. Data were 
permuted by the wavelet-based method described and characterized previously (Bullmore et 
al., 2001), which permits data driven calculation of the null distribution of SSQ under the 
assumption of no experimentally-determined response. This distribution can then be used to 
threshold the activation maps at any desired type 1 error rate. Activated voxels were then 
grouped into clusters using a method described before (Bullmore et al., 1999b), which has 
been shown to give excellent cluster-wise type 1 error control. SSQ ratio maps for each 
individual were transformed into standard stereotactic space (Talairach and Tournoux, 1988) 
using a two-stage warping procedure (Brammer et al., 1997) for the purpose of localization of 
activations. As a first step, an average image intensity map for each individual over the 
course of the experiment was computed. We then computed the transformations required to 
map this image to the structural scan for each individual and then from ‘structural space’ to 
the Talairach template by maximizing the correlation between the images at each stage. The 
SSQ ratio and BOLD effect size maps were then transformed into Talairach space using 
these transformations. Group activation maps were computed for each group (TP vs NP or 
TA vs NA) in each drug condition by determining the median SSQ ratio at each voxel (over all 
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individuals) in the observed and permuted data maps. Medians were used to minimize outlier 
effects. The distribution of median SSQ ratios over all intracerebral voxels from the permuted 
data was then used to derive the null distribution of SSQ ratios. This allows group activation 
maps to be thresholded at the desired voxel or cluster-level type 1 error rate. This gave group 
activation maps for each condition that could be compared against each other using non-
parametric repeated-measure analysis of variance (ANOVA) (Brammer et al., 1997). The 
voxel-wise statistical threshold was set at p=0.05 and the cluster-wise thresholds were 
adjusted to ensure that the number of false positive clusters per brain would be <1 (regions 
that survive this critical statistical threshold and the corresponding p values are reported). 
This excluded any areas of activation, which did not meet this threshold of significance. By 
conducting analyses at a cluster-level, data from more than one voxel is integrated into the 
test statistic giving greater sensitivity and it also allows for a reduction in the search volume or 
overall number of required tests for whole brain analysis. In comparison to analysis at the 
voxel level, cluster level analyses thereby helps mitigate the multiple comparisons problem. 
For each drug condition, we contrasted each of the active (encoding or recall) conditions of 
the verbal memory task against the baseline (fonts) condition at the individual subject level to 
generate contrast of interest map (‘encoding minus baseline’ and for ‘recall minus baseline’ 
conditions) for each subject, which were used for subsequent group-level analyses. As the 
baseline condition of the task was designed to keep learning to a minimum this analysis was 
used to exclude those areas that were involved in the completion of a task involving verbal 
stimuli but that were not crucial to learning and memory.  
Analysis of variance compared the TP group and NP during the placebo condition in order to 
assess differences in functional activation during the contrast of interest (for ‘encoding minus 
baseline’ and for ‘recall minus baseline’ conditions) in the absence of THC. Henceforth, for 
the purposes of simplicity, ‘encoding minus baseline’ and ‘recall minus baseline’ contrasts will 
be referred to as ‘encoding’ and ‘recall’ respectively, unless otherwise specified. To test the 
robustness of these group differences in activation and whether they were driven by outliers, 
we carried out a ‘leave one subject out’ (LOSO) analysis, which involved repeating the 
ANOVA with a different subject from the TP group being left out on each repeat. A total of 14 
repeat ANOVAs were carried out, once with each of the 14 TP subjects being left out. We 
then examined whether these neural activation differences during the encoding and recall 
conditions were specific to the sub-groups classified according to sensitivity to the 
psychotomimetic effects of THC (TP vs NP) or were similar to that between subgroups 
classified based on sensitivity to anxiogenic effects of THC (TA vs NA). One-way analysis of 
variance compared task-related neural activation differences (during encoding and recall 
conditions) between the TA and NA groups under the placebo condition to examine whether 
similar group differences exist between TA and NA groups as between TP and NP groups. 
Further, comparisons (using 2-way ANOVA) were then made between the drug given, TP and 
NP groups and the interaction of effects between them. The statistical values of the brain 
regions (clusters) differentially activated in these analyses, which were the mean of the SSQ 
ratio values of all the voxels in the respective clusters, were extracted to an IBM SPSS 
version 22 (IBM Corp. Released 2013; IBM SPSS Statistics for Windows, Version 22.0. 
Armonk, NY: IBM Corp.), where they could be plotted into graphs accompanying the brain 
activation maps. They were also used to identify correlation with behavioural data. A similar 
approach was employed to compare TA and NA groups. 
 
Social demographic and behavioural analysis 
 
Behavioural data was recorded and analysed using SPSS version 22 (see above). 
Comparisons between the socio-demographic characteristics of the two groups (such as 
age, NART score and number of years in education) and task performance (recall score) 
were carried out using two-sample t-tests. Differences in symptomatic data between the 
groups at 2 hours after THC and placebo administration did not fit normal distribution. 
Mann-whitney U tests were therefore used to assess differences in the means. We used 
the 2-hour time point because this is around the time that THC level peaked in peripheral 
blood and because scans were acquired closer to this time point (between 1-2hrs).  
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Supplementary Tables: 
 
 
 
Supplementary Table 1A: Previous exposure to psychoactive 
substances in study participants 
Lifetime Illicit drug use 
Cannabis  <5 times: 12 subjects; 
5-25 times: 24 subjects 
Amphetamines 5 subjects*/¥ (4 subjects had experimented a few times and 
1 had used small quantities from time to time)  
LSD/ Psilocybin 10 subjects ‡ (all had experimented a few times) 
Cocaine  3 subjects (all had experimented a few times) 
Opiate  2 subjects (both had experimented a few times) 
MDMA 11 subjects**/***; (all of them had experimented a few 
times) 
Other psychoactive substances (current use) 
Nicotine 
 
 
 
 
9 subjects; 
Mean number of cigarettes smoked/ day- 1.19 (SD-3.18) 
(range 0-15/ day); 
2 subjects smoked >10 cigarettes/day lifetime; only 1 
subject smoked at that level at the time of the study. 
Caffeine 33 subjects; Mean number of cups of coffee, tea or 
caffeinated drinks/ day- 2.42 (SD- 1.86) (range 0-11) 
* 1 subject had experimented with both amphetamines and LSD/Psilocybin 
¥ 1 subject had used amphetamines once a day for 4 weeks about 4 years 
before study 
‡ 1 subject had experimented with both opiates & Psilocybin  
** 1 subject had experimented with both LSD/ Psilocybin and MDMA 
*** 1 subject had experimented with both MDMA and opiates. 
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Supplementary Table 1B: Previous exposure to psychoactive 
substances in the two subgroups (Transiently psychotic: TP; Non-
psychotic: NP) of study participants 
 
Lifetime Alcohol and Illicit drug use 
Psychoactive 
substance 
Pattern of use (n) TP  NP p value 
Alcohol  Drinks only at weekends 
(moderate amounts)  
8 8 p>0.1 
Drinks everyday in moderate 
amounts  
2 5 
Drinks occasionally  3 8 
Drinks everyday moderately, 
some days is drunk  
1 1 
Amphetamines  No use 10 21 p>0.1 
Experimental use 3 1 
Occasional use (small 
quantities from time to time) 
1 0 
LSD/ Psilocybin  No use 11 15 p>0.1 
Experimental use 3 7 
Occasional use (small 
quantities from time to time) 
0 0 
Cocaine  No use 13 20 p>0.1 
Experimental use 1 2 
Occasional use (small 
quantities from time to time) 
0 0 
Opiate  No use 13 21 p>0.1 
Experimental use 1 1 
Occasional use (small 
quantities from time to time) 
0 0 
MDMA No use 10 15 p>0.1 
Experimental use 4 7 
Occasional use (small 
quantities from time to time) 
0 0 
Other psychoactive substances (current use)    
Nicotine (number of cigarettes/ day) (Mean±SD) 1.36 
(3.97) 
1.09 
(2.66) 
0.81 
Cannabis (number of times lifetime) (Mean±SD) 12.28 
(7.67) 
14.16 
(7.02) 
0.47 
Caffeine (number of cups of coffee) (Mean±SD) 2.45 
(2.18) 
2.40 
(1.68) 
0.95 
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Supplementary Table 2. Symptomatic and task performance data. 
Table showing the mean and standard deviation (SD) values for the positive and 
negative symptom subscale (PANSS) total score, each of the PANSS subscales, State-
trait anxiety inventory- state subscale (STAI), Analogue intoxication scale (AIS) and 
recall scores. Data shown is for 2 hours after ∆9-tetrahydrocannabinol (THC) and 
placebo (PLB) administration. 
 Transiently 
psychotic 
Mean (SD) 
Non-
psychotic 
Mean (SD) 
p value Transiently 
anxious 
Mean (SD) 
Non-
anxious 
Mean (SD) 
p 
value 
PANSS positive 
symptoms  
      
2 hrs after PLB treatment 7.36 (0.75) 7.55 (1.01)  0.77 7.22 (0.54) 7.28 (0.57) 0.79 
2 hrs after THC treatment  13.00 (3.70) 7.23 (0.69) <0.001 10.28 (4.04) 8.94 (3.03) 0.18 
PANSS negative 
symptoms 
      
2 hrs after PLB treatment 7.50 (1.87) 7.41 (1.14) 0.64 7.50 (1.24) 7.39 (1.65) 0.44 
2 hrs after THC treatment  10.29 (2.61) 7.91 (1.63) <0.001 9.56 (2.17) 8.11 (2.34) 0.037 
PANSS general 
psychopathology score 
      
2 hrs after PLB treatment 17.29 (2.01) 16.68 (1.39) 0.911 17.00 (1.53) 16.83 (1.82) 0.50 
2 hrs after THC treatment 25.93 (5.66) 19.23 (3.18) <0.001 23.22 (5.81) 20.44 (4.65) 0.097 
PANSS total score        
2 hrs after PLB treatment 32.14 (3.90) 31.27 (2.47) 0.42 31.72 (2.82) 31.50 (3.4) 0.52 
2 hrs after THC treatment  49.00 (8.84) 34.59 (4.14) <0.001 43.06 (9.84) 37.33 (8.45) 0.05 
STAI state score       
2 hrs after PLB treatment 15.71 (8.94) 10.18 (7.67) 0.83 10.33 (6.87) 14.33 (9.66) 0.22 
2 hrs after THC treatment 26.79 (11.99) 15.55 (11.03) 0.008 24.72 (11.81) 15.11 (11.63) 0.016 
AIS score        
2 hrs after PLB treatment 2.08 (2.69) 1.27 (1.55) 0.40 2.03 (2.54) 1.27 (1.34) 0.88 
2 hrs after THC treatment  7.44 (2.08) 4.24 (2.82) 0.001 7.03 (1.80) 3.81 (2.97) <0.001 
Recall score        
Between 1-2 hrs after 
PLB treatment 
29.28 (4.82) 30.68 (1.70) 0.22 30.66 (2.08) 29.61 (4.17) 0.34 
Between 1-2 hrs after 
THC treatment 
30.00 (3.50) 30.18 (2.51) 0.85 30.22 (2.66) 30.00 (3.18) 0.22 
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Supplementary Table 3A. Brain regions engaged by the encoding 
condition of the verbal learning task independent of drug condition.  
Regions survive critical threshold of <1 false positive cluster 
 
 
 Talairach 
Coordinates 
Cluster size  
Area x y z No. of 
voxels 
p value 
Superior frontal gyrus 0 4 48 58 0.0035 
Precentral gyrus 
 
 
51 -7 37 196 0.0035 
54 -4 15 267 0.0035 
-47 -15 42 181 0.001 
-54 -7 9 6 0.001 
Postcentral gyrus -47 -11 15 46 0.001 
-43 -19 37 37 0.001 
Inferior frontal gyrus -29 30 -7 21 0.001 
22 30 9 126 0.0035 
Insula -36 15 4 128 0.001 
36 19 -2 9 0.0035 
Claustrum 29 19 4 59 0.0035 
Anterior cingulate/ medial prefrontal 
cortex 
-4 7 42 100 0.001 
Hippocampus 
 
-29 -41 4 16 
 
0.001 
-25 -15 -13 0.001 
36 -33 4 71 0.0035 
Parahippocampal gyrus / Amygdala 25 -7 -13 15 0.0035 
Parahippocampal gyrus -25 -15 -7 11 0.001 
Superior temporal gyrus 43 -26 -2 54 0.0035 
43 -26 -7 51 0.0035 
58 -30 9 4 0.0035 
Fusiform gyrus 22 -81 -13 23 0.0035 
-25 -44 15 57 0.001 
-18 -85 -13 0.001 
Lingual gyrus -11 -78 4 26 0.001 
 18 -81 4 84 0.0035 
Middle Occipital gyrus 25 -85 -7 74 0.0035 
Posterior cingulate -29 -41 9 12 0.001 
 18 -67 9 4 0.0035 
Cuneus -4 -78 15 12 0.001 
 11 -78 15 30 0.0035 
Striatum -18 -7 -2 24 0.001 
 -22 -37 20 7 0.001 
Cerebellum -36 -67 -18 37 0.001 
 36 -67 -24 22 0.0035 
 25 -81 -18  0.0035 
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Supplementary Table 3B. Brain regions engaged by the recall condition 
of the verbal learning task independent of the drug condition.  
Regions survive critical threshold of <1 false positive cluster 
 
 Talairach 
Coordinates 
Cluster 
size 
 
Area x y z No. of 
voxels 
p value 
Precentral gyrus -51 -7 9 280 0.001 
-40 -19 37 0.001 
-43 -15 48 0.001 
47 -11 31 137 0.003 
58 0 15 0.003 
51 -7 37 0.003 
Postcentral gyrus -43 -19 42 109 0.001 
Inferior frontal gyrus -43 15 -13 139 0.001 
Insula 43 -22 -2 44 0.003 
-29 26 4 89 0.001 
Superior Temporal Gyrus 54 -30 4 127 0.003 
36 -33 15 0.003 
-54 -4 4 62 0.001 
Middle Temporal Gyrus -54 -44 9 42 0.001 
Parahippocampal gyrus- 
Hippocampus 
-22 -19 -13 10 0.008 
Parahippocampal gyrus- Amygdala -25 0 -13  0.008 
Fusiform gyrus 22 -81 -13 8 0.003 
Lingual gyrus -11 -81 -7 95 0.008 
11 -74 -7 13 0.003 
Middle Occipital gyrus 29 -81 -7 6 0.003 
Precuneus -25 -63 48 131 0.008 
Cuneus -14 -74 15 55 0.008 
4 -74 20 13 0.003 
Thalamus -11 -19 15 87 0.008 
Caudate 18 -11 20 61 0.003 
18 -11 26 0.003 
Midbrain- substantia nigra -14 -19 -2 11 0.008 
Cerebellum 4 -67 -24 50 0.008 
4 -63 -13 0.008 
-4 -63 -18 48 0.008 
-32 -63 -13 0.008 
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Supplementary Table 4. Brain regions differentially engaged in those 
sensitive to psychotomimetic effects of THC (TP) versus those who 
were not (NP) during the encoding and recall conditions of the verbal 
learning task under placebo and under THC.  
Unless otherwise stated, regions survive critical threshold of <1 false positive cluster. a 
These clusters did not survive the threshold to yield <1 false positive cluster.  
 Talairach Coordinates Cluster size  
Area x y z No. of voxels p value  
Group effect on task under placebo 
condition 
     
  Encoding condition  
    (TP>NP) 
      L. Hippocampus -29 -11 -13 59 0.001 
      R. Superior Temporal Gyrus 58 -26 4 43 0.004 
      L. Anterior cingulate -11 41 -2 33 0.006 
      R. Precentral gyrus 36 -15 31 39 0.004 
      L. Paracentral lobule -18 -41 48 58 0.002 
     (NP>TP)      
      R. Cerebellum, posterior lobe 14 -59 -13 50 0.004 
      L. Cerebellum, posterior lobe -33 -67 -13 121 0.0002 
 Recall condition      
  (TP>NP)      
   R. Cerebellum, anterior lobe 7 -52 -24 32 0.01 
   R. Middle Temporal gyrus 47 -15 -13 43 0.002 
   L. Medial Frontal gyrus,  0 48 31 33 0.01 
  (NP>TP)      
   R. Cerebellum, posterior lobe 33 -74 -18 67 <0.001 
   R. Precuneus 25 -56 31 75 <0.001 
   R. Precentral gyrus 51 0 26 24 0.005 
   L. Precentral gyrus -33 11 31 34 0.006 
   L. Inferior Parietal lobule -29 -41 26 46 0.006 
   R. Cingulate gyrus 14 -37 20 69 0.003 
Group (TP vs NP) X drug Interaction 
(THC vs Placebo)    
  
 Encoding condition      
   L. cerebellum, anterior lobe -18 -59 -24 118 0.003 
   R. Middle frontal gyrus 32 -4 42 67 0.001 
   R. Precentral gyrus 32 -7 37 33 0.001 
   L. Cingulate gyrus -4 -15 37 106 0.001 
 Recall condition a      
  R. Cerebellum, posterior lobe 4 -44 -40 57 <0.05 
  R. Superior temporal gyrus 51 0 4 26 <0.05 
  L. Insula -29 22 4 26 <0.05 
  R. Lingual gyrus 7 -70 4 32 <0.05 
  L. Superior Frontal gyrus  -25 48 20 31 <0.05 
  R. Precentral gyrus 51 -15 31 33 <0.05 
  L. Inferior Parietal lobule -43 -52 37 11 <0.05 
  R. Insula 32 -41 26 39 <0.05 
  L. Precentral gyrus -43 -4 42 11 <0.05 
  L. cingulate gyrus 7 4 31 49 <0.05 
  L. Precuneus -7 -70 48 20 <0.05 
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Supplementary Table 5. Brain regions differentially engaged in those 
sensitive to anxiogenic effects of THC (TA) versus those who were not 
(NA) during the encoding and recall conditions of the verbal learning 
task  
Regions survive critical threshold of <1 false positive cluster. 
 
 Talairach Coordinates Cluster size  
Area x y z No. of voxels p value  
Group effect on task in 
the absence of THC 
     
  Encoding condition  
    (TA>NA) 
      L. Fusiform gyrus -25 -74 -13 38 0.002 
      L. Precuneus -25 -67 37 36 0.005 
      L. Middle Frontal gyrus -32 15 42 23 0.006 
 Recall condition      
  (TA>NA)      
   R. Fusiform gyrus/ 
Cerebellum 43 -63 -13 
32 0.006 
  (NA>TA)      
   L. Caudate -14 4 20 65 0.002 
   L. Cingulate Gyrus -11 -26 37 46 0.003 
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Supplementary Figures: 
 
 
Supplementary Figure 1: Task performance: effect of drug 
Line graphs showing recall task performance (Mean; error-bars 
represent standard error of mean) over repeated trials of the verbal 
learning task under the placebo (dashed black line) and THC 
(continuous green line) conditions. 
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Supplementary Figure 2A: Brain regions activated by the encoding 
condition of the verbal paired associate task independent of repetition 
and drug condition (display threshold: cluster p <0.01) 
 
 
 
 
 
Supplementary Figure 2B: Brain regions activated by the recall 
condition of the verbal paired associate task independent of repetition 
and drug condition (display threshold: cluster p <0.01) 
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Supplementary Figure 3: Significant differences in brain activity 
between TP and NP groups in the placebo condition during the recall 
condition of the verbal paired associate task  
A. Greater engagement in the TP group relative to the NP group in the left medial frontal 
(1) and right middle temporal (2) gyri and cerebellum (3); (display threshold: cluster p 
<0.015). 
B.  Greater engagement in the NP group relative to the TP group in the left inferior 
parietal lobule (1), precentral gyrus (2) bilaterally, precuneus (3) and cingulate (4) 
gyrus on the right side and cerebellum (5); (display threshold: cluster p <0.007). 
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Supplementary Figure 4: Significant differences in brain activity 
between TA and NA groups in the placebo condition during the 
encoding condition of the verbal paired associate task  
Greater engagement (shown in red) in the TA group relative to the NA group (A & B) in the 
left fusiform gyrus (1), precuneus (2) and middle frontal gyrus (3) (cross-hair); (display 
threshold: cluster p <0.01). 
 
 
 
 
Supplementary Figure 5: Significant differences in brain activity 
between TA and NA groups in the placebo condition during the recall 
condition of the verbal paired associate task  
A. Greater engagement (shown in red) in the TA group relative to the NA group in the right 
fusiform gyrus (cross-hair; 1) extending to the cerebellum; (display threshold: cluster p <0.01). 
B. Greater engagement (shown in blue) in the NA group relative to the TA group in the body 
of caudate (cross-hair; 2) and cingulate gyrus on the left side; (display threshold: cluster p 
<0.01). 
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Responses to reviewers' comments: Please find below itemized responses to the 
reviewers’ comments. Changes made in the text in response to the comments are sign-
posted here with the changed sections marked here in italicized bold font. 
 
Reviewer #1: PSM-D-17-00440 
Increased hippocampal engagement during learning as a marker of sensitivity to 
psychotomimetic effects of delta-9-THC 
 
Comment 1.1: Bhattacharyya and colleagues conducted an interesting, innovative 
study based on a sound experimental paradigm (i.e., robust task, pseudo-randomised, 
double-blind, repeated measures, within-subject, cross-over design) to examine the 
neural correlates (hippocampus activity) of sensitivity of psychomimetic effects of 
THC, which varies greatly amongst individuals. Authors examined 36 healthy males 
under identical conditions under the influence of placebo or THC (10 mg) given 
orally, on two separate occasions, and measured psychopathology and brain activity 
during a verbal learning fMRI task. Participants were classified into those who did 
(TP) and did not (NP) experience transient psychotic symptoms after THC or placebo 
intake.  Hippocampus activity (during verbal encoding) was higher in TP under 
placebo and positively correlated with THC-induced transient psychotic symptoms. 
There was no difference between two participants grouped by sensitivity to THC-
induce anxiety. Authors conclude that altered hippocampal activation (during verbal 
encoding) may signal sensitivity to THC acute psychotomimetic effects. 
 
The manuscript is of good quality and is well written, there are some minor concerns. 
Response 1.1: Thank you. 
Response to Reviewers
 Comment 1.2: There are many main analyses (n = 4), but a small sample size (n = 
36). The rationale focuses on transient psychotic (not anxiety) symptoms. The 
analysis of anxiety seems exploratory and the number of analyses could be reduced by 
explicitly treating this analysis as exploratory or by removing the NA and PA group 
comparison, or in other ways justified by authors. 
Response 1.2: Thank you. We have now reported these as exploratory analyses as 
suggested. The changes made are listed below: 
 
‘Introduction’ (Page 8, Para 2): 
“Furthermore, we carried out exploratory analysis to investigate whether the 
difference in neurophysiological response between TP and NP under placebo 
condition was a specific biomarker for THC-induced psychotomimetic effects as 
opposed to acute……” 
 
‘Methods and Materials’ (Page 10, Para 1): 
“For our exploratory analyses, participants were classified into those who 
experienced transient anxiety (TA) and those…..” 
 
Page 12, Para 4:  
“We then carried out exploratory analyses to examine whether these brain activation 
differences during the encoding and recall conditions were specific to the sub-
groups…….”  
 
‘Results’ (Page 17, Para 2): “Exploratory one-way analysis of variance revealed 
significant…….” 
 
‘Discussion’ (Page 19, Para 1): “Difference in hippocampal engagement distinguished 
individuals sensitive to the psychotomimetic effects of THC but not those who 
experienced anxiety under THC as revealed in exploratory analyses, suggesting the 
relationship was specific to psychotic symptoms.” 
 
Comment 1.3: The overlap between individuals from the subgroups based on anxiety 
and psychosis could be clearer, as well as whether transient anxiety and psychotic 
symptoms are strongly related. Authors may consider controlling for anxiety when 
comparing brain activity in the TP and NP groups, and vice versa. 
Response 1.3: Thank you. We have now reported the overlap between the subgroups 
based on psychotic and anxiety symptoms as well as the correlation between anxiety 
and psychotic symptoms as shown below: 
 
‘Results’ (Para 1, Page 15): “Of the 14 TP participants, 8 were also in the TA 
group based on their anxiety ratings and 6 were in the NA group. Of the 22 NP 
participants, 10 were in the TA and 12 in the NA group. There was a positive 
correlation (0.41, p=0.01) between transient psychotic symptoms (PANSS-Positive 
subscale) and anxiety (STAI) measured 2 hours after administration of THC.” 
In response to suggestion to control for anxiety and also in light of the correlation 
between anxiety and psychotic symptoms, we have now analysed the differences in 
activation between the TP and NP groups under placebo during the encoding 
condition after covarying for the severity of anxiety symptoms induced by THC. 
Group differences in brain activation are shown below: before (Figure 1A) and after 
(Figure 1B) covarying for anxiety. As is evident, controlling for anxiety does not 
affect the overall pattern and direction of results, especially the difference in 
hippocampal activation between TP and NP groups. Hence, we have amended the 
‘Results’ and the ‘Discussion’ section to reflect this. 
 
In ‘Results’ we have stated (Page 16, Para 1): “….As there was a direct correlation 
between the transient psychotic symptoms and anxiety induced following THC 
administration, post hoc, we compared the TP and NP groups during the encoding 
condition under placebo after controlling for the severity of anxiety symptoms 
induced under THC. This did not change the pattern and direction of results (data 
not shown, but available from the authors on request), particularly the difference in 
left hippocampal engagement between the TP and NP groups.” 
 
In Discussion we have stated (Page 19, Para 1): “This difference in hippocampal 
engagement persisted even after controlling for the severity of THC-induced 
anxiety suggesting that difference in hippocampal activation under placebo 
condition between the TP and NP individuals was not a marker of differential 
sensitivity to THC-induced anxiety in the same individuals.” 
Group effect on task under placebo condition– Encoding condition (TP>NP) [yellow 
box marks the clusters (in red) which show hippocampal activation]. 
  
Group effect on task under placebo condition after covarying for anxiety– Encoding 
condition (TP>NP) [yellow box marks the clusters (in red) which show hippocampal 
activation]. 
 
 
Comment 1.4: It is not always clear if hippocampal activity is higher in the TP group 
also when THC is administered in addition to placebo. 
Response 1.4: Thank you. We have now stated this clearly in the ‘Results’ section. 
‘Results’ (Page 18, Para 1): “There was no significant group (TP vs NP) by drug 
(THC vs Placebo) interaction in the left hippocampus where there was a 
difference between the ‘TP PLB’ and ‘NP PLB’ groups under placebo 
condition, nor was a similar difference observed between ‘TP THC’ and ‘NP 
THC’ groups under THC alone.” 
Comment 1.5: Please clarify if this sample was used in previous studies, to help form 
an impression on the complex neural mechanisms of acute THC effects. 
Response 1.5: Thank you. We have now made this clear as below: 
‘Introduction’ (Page 7, Para 2): “In the present study, we therefore re-analysed 
previously reported data acquired employing a verbal memory paradigm that 
engages the hippocampus (Bhattacharyya et al., 2012a) to examine whether……..” 
 
Comment 1.6: I found the labels for the subgroups a bit confusing, author may 
consider using labels intuitively closer to the different experimental conditions. 
Response 1.6: Thank you. We have now appended the drug condition to the group 
labels where appropriate, to make it easier to follow throughout the text: ‘TP PLB’, 
‘TP THC’, ‘NP THC’, ‘NP PLB’, ‘TA PLB’ or ‘NA PLB’. 
 
Comment 1.7: With four main aims and analysis, at times it was confusing to follow 
which section corresponds to which aim. The description of data analyses, results and 
discussion could refer to each of the aims more explicitly. 
Response 1.7: Thank you. We have now amended the ‘data analysis’ sub-section 
within the ‘Methods and Materials’ section and the ‘Results’ and ‘Discussion’ 
sections to link them with our stated aims. 
‘Methods and Materials’ (Page 12, Para 4):  
“To investigate our primary hypothesis that ‘TP PLB’ group would show greater 
hippocampal activation compared to the ‘NP PLB’ group, analysis of variance….” 
Page 13, Para 1: “To test our hypothesis that THC administration would modulate 
brain activation differently in the TP and NP groups, further, comparisons (using 2-
way ANOVA) were then made between the drug given….” 
Page 13, Para 1: “Statistical values from differentially activated brain clusters (mean 
of all voxels in the cluster) were used to identify correlation with behavioural data to 
test our hypothesis that difference in brain activation under the placebo condition 
between TP and NP groups would be directly associated with the magnitude of 
THC-induced psychotomimetic effects in the same individuals.” 
 
‘Results’ (Page 15, Para 3): “Investigation of our hypothesis that ‘TP PLB’ group 
would show greater hippocampal activation compared to the ‘NP PLB’ group 
showed that during the encoding condition” 
Page 17, Para 3: “Investigation of our hypothesis that THC administration would 
modulate brain activation differently in the TP and NP groups, reflecting the 
different symptomatic effects with two-way ANOVA [Group (TP vs NP)….” 
 
‘Discusssion’ (Page 19, Para 1): “This was consistent with our hypothesis that 
difference in brain activation under the placebo condition between TP and NP 
groups would be directly associated with the magnitude of THC-induced 
psychotomimetic effects in the same individuals.” 
Page 20, Para 2: “Consistent with our hypothesis that THC administration would 
modulate brain activation differently in the TP and NP groups, our second major 
finding….” 
 
Comment 1.8: Additional minor comments. 
Page:4 green fonts in page 3. 
Response 1.8: Apologies. This has now been corrected. 
 
Comment 1.9: Page 5, please remove the writing 'Text' 
Response 1.9: Thank you. Done. 
 
Comment 1.10: Page: 13 Data analysis, paragraph 1 and 3, could confirm which 
groups were compared in the group-level analyses. Was the repeated measure design 
used for symptom data analysis? 
Response 1.10: Thank you. We have now amended this section in line with this 
comment as shown below. As we only compared the symptoms between the groups 
(TP vs NP and TA vs NA) under the drug conditions (THC or placebo) separately as 
measured at the 2-hour post drug-administration time-point, they were not suitable for 
repeated measures analysis. We focused on this time-point as psychological effects 
peaked at 2 hours after THC administration (as already descried in the last sentence in 
Paragraph 3 under the ‘Methods and Materials’ section.  
 
‘Methods and Materials’ (Page 11, Para 3): 
“Psychological ratings and memory task performance were analyzed using SPSS 
version 22. Socio-demographic characteristics (such as age, NART score and number 
of years in education) and task performance (recall score) of the groups (TP vs NP 
and TA vs NA) were compared…” 
 
Page 12, Para 3: “For each drug condition, we contrasted each of the active (encoding 
or recall) conditions of the verbal memory task against the baseline (fonts) condition 
at the individual subject level to generate contrast of interest map (‘encoding minus 
baseline’ and for ‘recall minus baseline’ conditions) for each subject, which were 
used for subsequent group-level analyses (TP vs NP and TA vs NA). ” 
 
Comment 1.11: Page:21 In Limitations, authors may start with a different term than 
'however'. Another limitation is the study did not account for 'genetic […] and 
personality and familial factors [..] as well as the composition of cannabis' which 
authors recognise in the Introduction to affect the psychomimetic effects of cannabis.  
Response 1.11:We have omitted ‘However’ from the beginning of the sentence as 
suggested. We have now added this as a limitation as shown below: 
 
‘Discussion’ (Page 21, Para 2): “It is also worth noting the present study does not 
account for other factors such as genetic (Bhattacharyya et al., 2012a, 
Bhattacharyya et al., 2014, Di Forti et al., 2012, van Winkel et al., 2011) and 
personality and familial factors (Henquet et al., 2005, McGuire et al., 1995, Stirling 
et al., 2008) as well as the composition (Bhattacharyya et al., 2010) and dose 
(Schoeler et al., 2016c) of cannabis that may also underlie differential sensitivity to 
the effects of cannabis.” 
 
Comment 1.12: Different fonts are used in different sections of the manuscript. 
Response 1.12: Apologies. We have now corrected this. 
 
Comment 1.13: Figure 2d, could distinguish the cutoff differentiating the TP and NP 
groups. 
Response 1.13: Thank you. As we have described in the ‘Methods and Materials’ 
section, participants were “allocated to the TP group if they scored at least 3 or more 
on any of the PANSS positive subscale items that measured psychotic 
symptoms (Delusions, Hallucinations, Suspiciousness/ Persecution) during 
any of the time-points when ratings were obtained following THC administration 
(Atakan et al., 2013).” Hence, we did not use a cut-off based on total score on the 
PANSS positive subscale, instead using an item-level cut-off score based on those 
items that rate psychotic symptoms in the subscale. Therefore, it would be misleading 
to label such a cut-off on figure 2D, which plots (on the y-axis) the change in PANSS 
positive subscale ratings following THC administration rather than individual item 
ratings that were used to determine group (TP vs NP) membership. As we have 
reported in Supplementary Table 2, at the 2 hour time-point (at which most subjects 
experienced peak ratings following THC administration), this reflected a score 
(mean±SD) of 13.00±3.70 in TP and 7.23±0.69 in NP group. Given that the least 
score that is possible on the PANSS positive subscale is 7, this corresponds to 
approximately a mean 6 point change in the TP group and less than 1 on the NP 
group, as is also evident from Figure 2D. 
Comment 2.1: Reviewer #2: This study used fMRI method to investigate 
hippocampus activity during a verbal learning task in subjects that were sensitive to 
THC relative to subjects that were not. The authors found the difference of 
hippocampus activity, which was correlated with transient psychotic symptoms 
induced by THC. The study design and results are meaningful in finding a imaging 
biomarker that might be further detect THC effect. I have three major concerns: 
1, small sample size in subgroups. If it's difficult to enlarge, the authors should at least 
mention it in discussion session under limitations. 
Response 2.1: Thank you. Unfortunately, the present cohort is not possible to extend 
as the scanner on which this data was acquired has since been decommissioned. 
However, we understand the importance of replication of this data in larger cohorts 
and have now addressed this limitation in the ‘Discussion’ section as below: 
 
‘Discussion’ (Page 23, Para 2): “Finally, the relatively modest sample size of the 
present cohort should also be noted, highlighting the need for independent 
replication in larger samples.” 
 
Comment 2.2: 2, The results of middle frontal gyrus should be further discussed. 
Response 2.2: Thank you. We have now discussed these results further as shown 
below: 
‘Discussion’ (Page 20, Para 2): “Attenuation of lateral prefrontal activity by THC in 
our study correlated with the increase in psychotic symptoms induced by it, and is 
consistent with a similar attenuation of lateral prefrontal activity(Bhattacharyya et 
al., 2015a) by THC that correlated with the severity of psychotic 
symptoms(Bhattacharyya et al., 2015a) induced by it as well as genetic 
moderation(Bhattacharyya et al., 2014) of the effects of THC in this region in the 
context of a cognitive activation task that engaged inhibitory control processes. 
Altered brain activity in this region has also been shown in the context of inhibitory 
and related motor control tasks in cannabis users both under acute THC challenge 
condition(Weinstein et al., 2008) and in its absence(Eldreth et al., 2004, Tapert et 
al., 2007). The lateral prefrontal cortex is rich in CB1 receptors(Elphick and 
Egertova, 2001), the main target of THC in the brain(Pertwee, 2008), and results 
presented here suggest that the effects of THC in this region may be involved in the 
generation of paranoia under its influence consistent with dorsolateral prefrontal 
hypoactivity reported in schizophrenia (Callicott et al., 2000) and role of altered 
lateral prefrontal activity in the pathophysiology of psychotic symptoms in 
schizophrenia(Shergill et al., 2000). ” 
 
Comment 2.3: 3, The authors should realize the difference between acute and chronic 
effect of THC. In the introduction and discussion session, using acute effect of THC 
in terms of psychotic symptoms, should be differentiate from schizophrenia, which is 
a chronic disease. Also, acute and chronic effect of THC should be different, and may 
be opposite. 
Response 2.3: Thank you. The reviewer suggests that we may have conflated the 
acute and chronic effects of THC and also between acute effects of THC in terms of 
psychotic symptoms induced by it and schizophrenia. However, in the introduction, 
we have clearly indicated the transient nature of psychotic symptoms induced by THC 
acutely as here “Consistent with this, delta-9-tetrahydrocannabinol (THC), the main 
psychoactive ingredient in cannabis has been shown in experimental studies to induce 
transient psychotic symptoms in healthy subjects (Bhattacharyya et al., 2015a, 
Bhattacharyya et al., 2009, D'Souza et al., 2004, Morrison et al., 2011) and 
exacerbate them in schizophrenia patients (D'Souza et al., 2005, Henquet et 
al., 2006).” While agreeing with the authors contention that the acute effects of THC 
are different from schizophrenia, we would also like to reiterate that the acute and 
transient psychotomimetic effects of THC are of particular interest because of the 
association between regular cannabis use and development of psychotic disorders 
such as schizophrenia. Similarities between the acute cognitive effects of THC and 
those also noted in schizophrenia, e.g., memory impairments are, therefore of interest, 
and have been presented to help make the case for the hypotheses that we have tested 
here. In the ‘Discussion’, we had also explicitly stated that “It is worth noting that 
psychotic-like symptoms experienced by participants in this study were transient and 
self-limited unlike those observed in established psychosis, but…”. Finally, in the last 
sentence in the Discussion section of the paper we had stated that, “While one may 
speculate that altered hippocampal activation may also predict sensitivity to the onset 
of psychotic disorders or a relapse of psychosis following regular cannabis use, this 
was not tested here and will require further investigation in prospective studies.” 
Hence, we believe that we have explicitly attempted not to conflate the acute effects 
of THC with schizophrenia. In response to this comment, we have further amended 
the ‘Discussion’ section (Page 19, end of Para 1) as shown here: “This is consistent 
with evidence of increased resting hippocampal regional cerebral blood flow (Allen et 
al., 2015) in those at high clinical risk of psychosis and reduced hippocampal volume 
in those with established schizophrenia (Nelson et al., 1998). However, it is worth 
noting that it is regular rather than acute cannabis use that has been linked to 
schizophrenia. Hence, while altered left hippocampal engagement may be a marker 
of sensitivity to the acute psychotomimetic effects of THC, it may not necessarily be 
a marker of sensitivity to the development of schizophrenia following regular 
cannabis use. ”. 
We shall be grateful if the reviewer could suggest any specific examples as to where 
we may have conflated the acute effects of THC with schizophrenia, which we would 
be happy to amend. 
 
Comment 3.1: Reviewer #3: The authors Bhattacharyya et al. report results from a 
functional MRI study using an acute drug challenge to test the effects of oral THC on 
brain activation during a verbal memory task. In this work subjects are separated 
according to whether they experienced transient psychotic symptoms following the 
THC administration or not. Interestingly, hippocampal activation during the placebo 
condition was specific to subjects experiencing transient psychotic symptoms when 
given THC.  
Overall this is a very well conducted study and the authors are well-known in the field 
for their work in cannabis and psychosis. I would have a few minor suggestions to 
improve the manuscript: 
Response 3.1: Thank you. 
 
Comment 3.2: - Table 1: Could the authors report the measures that are reported? I 
am assuming it is means and standard deviations in brackets? 
Response 3.2: Apologies for this oversight. We have now clarified that SD stands for 
standard deviation (reported within brackets) as a legend to Table 1. We have 
indicated that the values reported are ‘Means’. 
 
 
Comment 3.3: - Figure 1 A: It seems like subjects with transient psychotic symptoms 
and those without differ with respect to their STAI scores (even at baseline). This 
should be discussed. Could it be a potential confound? 
Response 3.3: Thank you. In response to this comment and also comment 1.3 
(above), we have now analysed the differences in activation between the TP and NP 
groups under placebo during the encoding condition after covarying for the severity 
of anxiety symptoms (STAI scores) induced by THC. As is evident from the results of 
this analysis (please see response to comment 1.3, where we have described these 
results in detail and the corresponding changes made in the text), controlling for 
anxiety does not affect the overall pattern and direction of results, especially the 
difference in hippocampal activation between TP and NP groups. Hence, we have 
amended the ‘Results’ and the ‘Discussion’ section to reflect this (details shown in 
response to comment 1.3). 
 
Comment 3.4: - There are a couple of typos (e.g wrong brackets in the paragraph 
image acquisition) 
Response 3.4: Thank you. We have now amended this section. 
 
Comment 3.5: - In order to test for the specificity of THC-related effects on brain 
function, the authors also report contrasts between transient-anxious participants and 
non-anxious participants. Also the demographics for these subgroups are reported. I 
think it would also be important to note the overlap between those two groups (e.g. 
were subjects that experienced transient psychotic symptoms also more likely to 
experience transient anxiety?). 
Response 3.5: Thank you. We have now reported the overlap between those who 
experienced transient psychotic and those experienced anxiety symptoms (please see 
response to comment 1.3).  
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Dear Editor 
 
Re: Manuscript: “Increased hippocampal engagement during 
learning as a marker of sensitivity to transient 
psychotomimetic effects of delta-9-THC”  
 
 
Thank you for reviewing our manuscript and giving us the opportunity to 
submit a revised version.  
 
Please find attached the revised version, wherein we believe that we have 
addressed all the issues raised by the reviewers. Please also find attached a 
point-by-point response to reviewers.  
 
We hope that the manuscript in its present form will be acceptable for 
publication in your journal. 
 
Yours sincerely 
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Cover Letter to Editor
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